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The risk of second malignant neoplasms (SMNs) following prostate radiotherapy is a concern
due to the large population of survivors and decreasing age at diagnosis. It is known that
parallel-opposed beam proton therapy carries a lower risk than photon IMRT. However, a
comparison of SMN risk following proton and photon arc therapies has not previously been
reported. The purpose of this study was to predict the ratio of excess relative risk (RRR) of
SMN incidence following proton arc therapy to that after volumetric modulated arc therapy
(VMAT). Additionally, we investigated the impact of margin size and the effect of riskminimized proton beam weighting on predicted RRR. Physician-approved treatment plans were
created for both modalities for three patients. Therapeutic dose was obtained with differential
dose-volume histograms from the treatment planning system, and stray dose was estimated
from the literature or calculated with Monte Carlo simulations. Then, various risk models were
applied to the total dose. Additional treatment plans were also investigated with varying margin
size and risk-minimized proton beam weighting. The mean RRR ranged from 0.74 to 0.99,
depending on risk model. The additional treatment plans revealed that the RRR remained
approximately constant with varying margin size, and that the predicted RRR was reduced by
12% using a risk-minimized proton arc therapy planning technique. In conclusion, proton arc
therapy was found to provide an advantage over VMAT in regard to predicted risk of SMN
v

following prostate radiotherapy. This advantage was independent of margin size and was
amplified with risk-optimized proton beam weighting.
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Chapter 1
Introduction
This chapter contains an introduction to prostate cancer (section 1.1) as well as external
beam photon (section 1.2.1) and proton (section 1.2.2) radiotherapy techniques. The risk of
second malignant neoplasms from radiation therapy (section 1.3) will be briefly reviewed.
Finally, the statement of the problem (section 1.4) is followed by the hypothesis and specific
aims (section 1.5).
1.1. Prostate Cancer
Prostate cancer is a disease with a large incidence and a high survival rate, which translates
into a substantial population of survivors. It is the most common cancer in men, excluding nonmelanoma skin cancer, with approximately 217,730 new prostate cancer cases diagnosed in the
United States in 2010 (Jemal et al., 2010). Most cases of prostate cancer are curable; the
relative 5-year survival rate is nearly 100% and the relative 10-year survival rate is 91%
(American Cancer Society, 2011). Consequently, as of 2007, there were approximately 2.3
million prostate cancer survivors in the United States (SEER, 2007).
Another factor contributing to the large population of prostate cancer survivors is that men
are being diagnosed with prostate cancer earlier in life and at an earlier stage of disease
progression. This is in part due to the development of the prostate-specific antigen (PSA) test, a
non-invasive blood test which is widely used in assessing a patient‟s risk of prostate cancer
(American Cancer Society, 2011). The mean age of diagnosis has decreased from 72 years in
1990 (Quinn and Babb, 2002) to approximately 67 years in 2007 (SEER, 2007).
There are multiple effective treatment options for men diagnosed with prostate cancer
including surgery, hormone therapy, external beam radiation therapy, and low and high dose
1

rate brachytherapy. Active surveillance is also an appropriate option for many men who have
asymptomatic and slow-growing tumors (American Cancer Society, 2011). The treatment
strategy for each specific case is determined by the physician and the patient and takes into
account factors like tumor stage, and the patient‟s age and overall health.
1.2. External Beam Radiation Therapy
External beam radiation therapy (EBRT) is a good treatment option for many patients and is
a component of approximately one third of all prostate cancer patients‟ therapy (Mettlin et al.,
1997; Virnig et al., 2002). EBRT is, in part, so prevalent due to its effectiveness. D‟Amico et
al. (1998) reported no statistical difference in biochemical outcomes in patients who were
treated with radical prostatectomy vs. EBRT for localized prostate cancer. Additionally, EBRT
has the advantage of being non-invasive and safer than radical prostatectomy for patients with
lower overall health status by eliminating surgery-specific risks, for example, the risk of
infection (Culver et al., 1991).
However, radiation therapy is not free from risk. Patients can experience acute or late
effects from radiation due to irradiation of normal tissues. For prostate radiotherapy, acute
effects can include urinary urgency or incontinence, bowel irritation, and rectal bleeding
(American Cancer Society, 2011), which usually resolve with time. Some patients experience
late effects of radiation; for example, patients who survive more than approximately five years
have an increased risk of developing secondary solid tumor due to radiation exposure (Brenner
et al., 2000).
1.2.1. Photon Therapy
Photons have been used for radiation therapy since the early 1900s after Roentgen
discovered the x-ray in 1895. Many technological advances have improved our ability to
deliver radiation dose accurately and precisely to tumors and minimize dose to normal tissue.
Medical megavoltage linear accelerators (linacs), invented in the 1960‟s, provided significant
2

skin sparing compared to lower energy x-ray therapy. Then, in the 1980s, computed
tomography (CT) imaging made it possible to visualize the target volume on a threedimensional (3-D) image. Additionally, it became possible to visualize the dose distribution
and anatomy in 3-D with treatment planning systems (TPSs). The standard of care then became
3-D conformal radiation therapy (3DCRT), which refers to radiotherapy that, in addition to
being planned in 3-D, is shaped in the beam‟s eye view around the target volume to reduce
dose to normal tissue. These advances facilitated prostate dose escalation from approximately
65 gray (Gy) to doses in the high 70s of Gy (Thompson, 2007). In the 1990s, intensity
modulated radiation therapy (IMRT) and image guided radiation therapy (IGRT) became
available, which provided additional improvement in accurately delivering conformal dose
distributions. In particular for prostate cancer, Zelefsky et al. (2000) showed that IMRT
improved coverage of the clinical target volume (CTV), decreased bladder and rectal doses,
and decreased the incidence of rectal bleeding compared to 3DCRT.
The current standard of care for photon EBRT for prostate cancer at The University of
Texas MD Anderson Cancer Center (MDACC) is IMRT. Linac based IMRT creates conformal
dose distributions with a multi-leaf collimator (MLC), which modulates the fluence of photons
across the two-dimensional cross-section of each beam. There are two ways that the MLC can
operate during the delivery of the treatment beam. The first way is dynamically, also known as
the sliding window technique, which is achieved by delivering the radiation while the leaves
move across the field. The second approach is for the beam to turn off while the leaves move to
the next position, only delivering radiation when the leaves are stationary. This second
technique is known as step-and-shoot, and is the method implemented at MDACC. Chui et al.
(2001) and Longobardi et al. (2005) compared the two techniques and found comparable
dosimetric quality and accuracy between the two (given adequate segments for step-and-shoot,
approximately 10 per beam). Chui et al. also found that sliding window required approximately
3

20% more monitor units (MUs), but that the overall treatment time was roughly two times
faster than the step-and-shoot method.
The first rotational intensity modulated photon radiotherapy technique, tomotherapy, was
proposed by Mackie and colleagues and published in 1993 (Mackie et al., 1993). In this
technique, intensity modulation is accomplished by delivering radiation in slices and setting
collimating leaves to either fully open or fully closed positions. The first clinical
implementation of this “slice therapy” was the PeacockTM system (Nomos Corporation,
Sewickley, PA), which used a MIMiCTM MLC mounted on a linac gantry (Carol, 1994; Carol,
1995; Mackie, 2006). Treatment was delivered serially, and the treatment couch was advanced
for the delivery of each adjacent slice. Then, TomoTherapy® Incorporated developed a CT
scanner type gantry with a linac that rotates and delivers radiation helically while the patient is
advanced continuously through the bore (Mackie et al., 1999; Yang et al., 1997; Mackie,
2006). With helical delivery, patient positioning errors were not as critical as with serial
delivery, where a 1 mm positioning error could cause dose errors of approximately 10-20%
(Carol et al., 1996; Low and Mutic, 1997). The new technique also significantly reduced the
treatment time, from the order of 30 minutes for serial delivery (Xia et al., 2000) to a mean
treatment time of 10.7 minutes for helical delivery (Sterzing et al., 2008).
A more recently introduced rotational intensity modulated photon radiotherapy technique,
which can be administered with a conventional linac, is volumetric modulated arc therapy
(VMAT). Unlike tomotherapy, an entire volume, instead of a slice, can be irradiated in single
rotation and with a fixed couch position. The specific method was first published by Otto in
2008 (Otto, 2008), which expanded on a method proposed and developed by Yu (1995). Both
dose rate and rotation speed are varied during beam delivery, providing additional degrees of
freedom in treatment planning. The VMAT optimization algorithm described by Otto was
implemented in the Eclipse (Varian Medical Systems, Palo Alto, CA) TPS, which
4

approximates an arc as multiple static beams, starting with a low resolution and increasing to
177 beams as it optimizes, while constraining both the dose rate and the MLC motion to take
into account the mechanical and radiation limitations of the linac and MLC (Otto, 2008). Our
institution has treated a small number of patients with VMAT since 2009, including patients
with prostate cancer. To date, it appears that the main advantage of this technique is shorter
treatment times while preserving plan quality comparable to IMRT (Kjaer-Kristoffersen et al.,
2009; Zhang et al., 2009; Palma et al., 2008; Bedford and Warrington, 2009). Otto reported
treatment times between about 1.5 to 3 minutes for one arc. Specifically, delivery time for a
one-arc nasopharynx VMAT treatment plan was 1.8 minutes, and delivery time for a
comparable 7-field nasopharynx IMRT plan was 7.1 minutes (Otto, 2008). The experience at
our institution is that two arcs are required for optimal treatment plans, yielding treatment
delivery times of approximately three minutes.
An undesirable aspect of all EBRT photon radiotherapy techniques is that the patient is also
exposed to some stray radiation. The sources of this stray radiation are photon leakage from the
treatment head and MLC leaves, photon scatter from the collimator and the patient, and, above
approximately 6 MeV, secondary neutrons produced by (γ,n) reactions in the treatment head
and, to a lesser degree, the patient (Howell et al., 2009; NCRP, 2005). In or near the treatment
field, scatter is the predominant source of stray radiation, whereas far from the treatment field,
leakage predominates (Kase et al., 1983; Stovall et al., 1995). Radiation exposures from
leakage and scatter photons and photoneutrons (for 10 MV photon beams and above) have been
measured and characterized for conventional therapy (Kase et al., 1983; Stovall et al., 2006),
IMRT (Kry et al., 2005b; Howell et al., 2006; Wang and Xu, 2008), and tomotherapy (Ramsey
et al., 2006). Also, Xu et al. (2008) have published a review on the topic. To our knowledge,
there have not been any reports on leakage and scatter exposures for VMAT. However, some
studies have implicitly made the assumption that the stray radiation dose from VMAT is
5

equivalent (per MU) to that from IMRT (Palma et al., 2008; Kjaer-Kristoffersen et al., 2009;
Wolff et al., 2009; Yoo et al., 2010). To date, VMAT has only been used with 6 MV, thus
secondary neutrons are not a concern.
1.2.2. Proton Therapy
Robert Wilson proposed the medical use of protons in the treatment of tumors in 1946
(Wilson, 1946). In his paper, Wilson described the advantageous dosimetric properties of
protons, namely, how they deposit a large portion of their dose in the last few millimeters of
their range near the peak of the Bragg curve (Figure 1.1). Beyond their range, determined by
their initial kinetic energy, the dose falls rapidly to almost zero, thus enabling sparing of the
tissue distal to the target.
Proton Bragg Peak 122.5 MeV
1.2

Relative Dose

1
0.8
0.6
0.4
0.2
0
3

5

7

9

11

depth (cm)

Figure 1.1 – Relative absorbed dose of a simulated Bragg curve from an unmodulated 122.5
MeV proton beam vs. depth in water.
The first therapeutic use of proton therapy in humans was for the pituitary gland in 1954
(Lawrence et al., 1958), then for brain tumors shortly after (Kjellberg et al., 1962; Larsson et
al., 1963; Kjellberg and Kliman, 1973; Munzenrider and Liebsch, 1999). Later, proton therapy
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was also extensively used in the treatment of ocular tumors, chordomas, and chondrosarcomas
(Munzenrider et al., 1980; Suit et al., 1982; Gragoudas, 1986; Munzenrider, 1999).
To date, over 67,000 patients have been treated with proton therapy, and there are
approximately 28 centers in operation world-wide (Particle Therapy Co-Operative Group,
2010). Of this large population of proton therapy patients, prostate cancer patients are the
majority (Sisterson, 2005), which have resulted in disease-free survival rates comparable to
other forms of local therapy and minimal morbidity (Slater et al., 2004; Nihei et al., 2010).
Proton therapy dose is prescribed differently than photon therapy dose. Proton beams are
believed by some to have a slightly higher relative biological effectiveness (RBE) compared to
photon beams (ICRU, 2007). To attempt to account for these differences, the ICRU
recommends a generic RBE value of 1.1 and that the dose be prescribed in units of Gy (RBE),
where DRBE[Gy (RBE)] = Dabsorbed[Gy]

RBE. This convention is controversial, but is widely

used.
There are two main methods to cover the cross-sectional area of a target volume with a
proton beam (Chu, 1993). The first method to provide lateral coverage of the target is to spread
the pencil beam into a larger field. The second method is to “sweep” the pencil beam across the
target using deflecting magnets. These two modes of delivery are referred to as passive
scattering and beam scanning (or active scanning), respectively, and passive scattering is far
more prevalent around the world (Sisterson, 2005).
Passive scattering is achieved by spreading the pencil beam of protons into a large, uniform
field with scattering foils. A double scattering approach was proposed by Koehler et al. (1977)
and uses a first scatterer to spread the beam, a central beam stop to eliminate the protons in the
center of the field, and then a second scatterer to further spread the beam to produce a large and
relatively uniform proton field. This approach was subsequently refined by Gottschalk and
others and is simple, safe, and versatile (Gottschalk et al., 1991).
7

It is also necessary to broaden the high dose region over the target volume in depth. A
proton‟s range is determined by its energy, where a higher energy results in a longer range.
Therefore, modulating the beam‟s energy will modulate the beam range. One method is to use a
range modulator wheel (RMW), which has steps of varying thickness of absorbing material to
modulate the range (Chu, 1993). The RMW rotates quickly through the beam to produce
multiple Bragg peaks with varying range. The summation of these modulated pristine peaks
produces a spread-out Bragg peak (SOBP) of a desired width (Figure 1.2). This was proposed
by Wilson (1946) and implemented by Koehler et al. (1975) at the Harvard Cyclotron
Laboratory.

Figure 1.2 – Relative absorbed dose from a spread-out Bragg peak, B, of 14.5 cm width
resulting from the sum of the pristine Bragg curves such as A (Koehler et al., 1975). The
depths and magnitudes of the shifted Bragg curves relative to A are denoted by the triangles
labeled1-17. Reprinted from Nuclear Instruments and Methods, 131, A.M. Koehler, R.J.
Schneider, J.M. Sisterson, Range modulators for protons and heavy ions, 438, 1975, with
permission from Elsevier
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After a proton beam is spread laterally (cross-field direction) and longitudinally (depth
direction), further modifications are required to conform the beam to the target volume. Beamspecific brass apertures are used to collimate the cross-section of the beam to the shape of the
target (Wagner, 1982). In addition, to conform the distal end of the SOBP to the target, a beamspecific range compensator is milled to pull the range of the protons back where necessary
(Wingate et al., 1977; Goitein, 1978; Wagner, 1982; Urie et al., 1984).
In recent years, interest in rotational delivery of proton beams has increased. To our
knowledge, the first appearance of proton arc therapy in the literature was in 1997, when three
separate groups published studies on the topic. The first publication was a simulation study for
a Ewing sarcoma treatment (Isacsson et al., 1997), the second publication was a phantom study
for a chest wall irradiation (Sandison et al., 1997), and the third publication was a patent for a
method and apparatus for proton arc therapy (Deasy, 1997). Since proton arc therapy‟s
appearance in the literature, various other papers have been published. Oelfke and Bortfeld
(2000) reported a factor of 2 – 3 reduction in integral dose to healthy tissue for inverse planned
proton arc therapy when compared to photon IMRT for a simulation of irradiation of a planar
circular target. Similarly, Flynn et al. (2007) found the integral dose was lowered by a factor of
about 2 for proton arc therapy compared to photon IMRT and helical tomotherapy. Sengbusch
et al. (2009) investigated the energy required to treat patients with proton arc therapy and found
that, with an AP arc and a PA arc, each subtending 90 degrees, 90% of the patients in their
study could be treated with a proton kinetic energy of 198 MeV or less. One particular design
for a compact proton accelerator capable of arc delivery is under commercial development by
TomoTherapy Incorporated (Madison, Wisconsin) in partnership with Lawrence Livermore
National Laboratory (Mackie et al., 2007; Caporaso et al., 2008; Chen, 2009). This design
proposes to use the dielectric wall accelerator technology to achieve a “one room” proton
therapy delivery system capable of simultaneous scanned beam delivery and gantry rotation.
9

One of the reasons for this interest in proton arc therapy is the potential improvement in
conformity that arc therapy could provide. Currently, IMRT rivals proton therapy with regard
to dose conformity due to the comparatively large number of treatment gantry angles used in
IMRT (Bortfeld, 2006; Trofimov et al., 2007). However, it is possible that by increasing the
number of beam angles (or a delivering through an arc) proton therapy could provide
significantly better conformity than IMRT or VMAT.
Theoretically, one can deliver proton arc therapy with current proton gantries using the
passive scattering technique. For example, the SOBP width can be varied throughout the
rotation by altering the gating of the beam through different steps of the range modulator
wheel. Then, the range could be varied by using a robotic wedge energy degrader (Chu, 1993;
Lu, 2008a, b; Titt et al., 2010; Melancon, 2010), and the shape of the beam could be defined by
a proton-appropriate MLC (Brahme et al., 1987; Chu, 1993; Bues et al., 2005; Slopsema and
Kooy, 2006; McDonough and Tinnel, 2007). While many technical aspects of proton arc
delivery still require research and development, there are no known fundamental obstacles to its
implementation.
One poorly understood aspect of proton arc therapy is the exposure of patients to stray
radiation. Similar to photon therapy, proton therapy patients are also exposed to stray radiation,
which originates from neutrons produced in (p, xn) reactions. These neutrons can be produced
externally by reactions in the treatment unit, or internally by reactions in the patient‟s body.
Since the spot scanning technique uses magnetic fields to laterally spread the beam instead of
scattering foils, external neutron production is comparatively small (Schneider et al., 2002).
However, with optimized design, neutron production in passively scattered proton treatment
units can be reduced (Tayama et al., 2006a; Taddei et al., 2008; Brenner and Hall, 2008;
Taddei et al., 2009a), diminishing the advantage of scanning delivery. The neutrons produced
in the passive scattering technique are dependent on the general construction of the beam
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nozzle and increases with increasing proton beam energy, increasing SOBP width, increasing
uncollimated proton field size, and decreasing aperture size (Yan et al., 2002; Mesoloras et al.,
2006; Zheng et al., 2008a; Taddei et al., 2008). Neutron dose values from the literature vary
dramatically between different facilities, suggesting a strong dependence on delivery technique,
facility design, and the method of measurement or simulation (a sample of which are plotted in
Figure 1.3) (Schneider et al., 2002; Yan et al., 2002; Fontenot et al., 2005b; Polf et al., 2005;
Hall, 2006; Mesoloras et al., 2006; Tayama et al., 2006a; Zheng et al., 2007a; Moyers et al.,
2008b; Wang et al., 2010; Yonai et al., 2010; Zhang et al., 2010; Clasie et al., 2010). These
values range from 0.025 millisieverts per gray (mSv/Gy) (Mesoloras et al., 2006) to 8.92
mSv/Gy (Schneider et al., 2002; Hall, 2006).

Figure 1.3 – Stray neutron equivalent dose per therapeutic absorbed dose (H/D) for proton
beams as a function of distance from proton field edge (Schneider et al., 2002; Yan et al., 2002;
Fontenot et al., 2005b; Polf et al., 2005; Hall, 2006; Mesoloras et al., 2006; Tayama et al.,
2006a; Zheng et al., 2007a). For comparison, values are also plotted for 6 MV IMRT (navy)
and 6 MV 4 field CRT (pink) (Hall, 2006).
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There have been some stray equivalent dose measurements and simulations specifically for
proton therapy of the prostate (Wroe et al., 2007; Fontenot et al., 2008; Zheng et al., 2008a;
Taddei et al., 2008; Wroe et al., 2009; Newhauser et al., 2009b; Yepes et al., 2009). For
example, Wroe et al. performed measurements at Loma Linda University Medical Center
(2007) and Massachusetts General Hospital (2009), which ranged from 0.1 mSv/Gy to 10
mSv/Gy, depending on facility and distance from isocenter. One study from our institution was
reported by Zheng et al. (2008a), in which the effective dose was found to be 8 mSv/Gy for
proton therapy of the prostate. Additionally, Fontenot et al. (2008) simulated stray neutron
doses resulting from a prostate therapy treatment at our institution and found doses ranging
from 1.9 mSv/Gy to 12.3 mSv/Gy, where dose decreased with increasing distance from
isocenter. In a similar study, Taddei et al. (2008) found equivalent doses ranging from 1.05
mSv/Gy to 19.7 mSv/Gy.
1.3. Risk of Second Malignant Neoplasms from Radiation Therapy
Ionizing radiation damages cells, and when damaged cells are not sterilized, they have the
potential to mutate and become carcinogenic (Preston et al., 2007). Therefore, patients
receiving radiation therapy are at increased risk for the development of a second primary
cancer, or second malignant neoplasm (SMN) (NRC, 2006).
Epidemiological studies on the risk of SMN incidence following prostate radiotherapy are
not coherent. Some studies report an increased risk of an SMN, including cancers of the
bladder and rectum (Brenner et al., 2000; Moon et al., 2006; Kendal et al., 2007). However,
one study reported an increased risk of bladder cancer but not rectal cancer (Curtis et al., 2006).
Interestingly, Chrouser et al. (2005) only found an increased risk of bladder cancer in those
patients who had a prostatectomy prior to radiotherapy, and Pickles and Phillips (2002) found
an increased risk of bladder cancer in non-irradiated patients but not in irradiated patients.
While much uncertainty remains regarding risk of SMN following prostate radiotherapy, the
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absolute risk of incidence of a radiogenic second malignant neoplasm is most likely on the
order of a percent or two: 0.3% for all patients, and 1.4% for patients who survive at least 10
years (Brenner et al., 2000).
While epidemiological data would be ideal for assessing risks, large follow-up times are
required and the quality and completeness of dosimetric information is often lacking; therefore,
it is not feasible to use any single epidemiological study predict patient-specific risk following
current radiotherapy techniques. In order to predict patient-specific risk of SMN incidence
following a particular radiotherapy treatment or to compare the predicted risk between different
treatments, a rigorous, reproducible, and well-understood method is required. First, an accurate
and complete knowledge of the dose distribution in the organs of interest is needed. Then, the
relationship between radiation dose and the risk of SMN incidence can be applied to the
dosimetric information. These methods were previously developed and applied to studies of
proton therapy and IMRT for prostate cancer (Kry et al., 2005a; Schneider et al., 2007; Taddei
et al., 2008; Fontenot et al., 2009; Bednarz et al., 2010), but not for arc therapies. The current
state of knowledge in radiation risk estimation is briefly reviewed below.
It is generally accepted that there is a linear-no-threshold (LNT) relationship between
equivalent doses and risk of cancer between 0 Sv and about 2.5 Sv (NCRP, 1993; NRC, 2006);
however, the relationship between dose and risk at higher doses is less well understood. At
higher doses, cell sterilization increases, and the general relationship between dose and risk for
most tissues most likely lies somewhere between a linear and a linear-exponential model (Hall
and Wuu, 2003; Sachs and Brenner, 2005; Schneider et al., 2007; Schneider et al., 2006;
Schneider et al., 2005).
Not surprisingly, different tissues have been shown to exhibit different risk relationships
with dose (Boice et al., 1988; Lindsay et al., 2001; Hall and Wuu, 2003; Dasu and Toma-Dasu,
2005; Schneider et al., 2005; Sachs and Brenner, 2005) (Figure 1.4). For example, risk of an
13

SMN in the thyroid has been shown to exhibit a linear-exponential relationship with dose,
increasing linearly to an inflection point at approximately 20 - 30 Gy, then decreasing at higher
doses (Thompson et al., 1994; Ron et al., 1995; Sigurdson et al., 2005; Ronckers et al., 2006;
Bhatti et al., 2010). In stark contrast, the risk of an SMN in the breast has been shown to
increase linearly to approximately 40 Gy while showing no evidence of decrease at high doses
(Travis et al., 2003; Travis et al., 2005; Inskip et al., 2009).
The dose-risk relationships of the bladder and rectum are of particular interest to this work.
For the bladder, some evidence indicates that the risk of an SMN may plateau beyond
approximately 10 Gy (Boice et al., 1988; Neugut et al., 1997; Brenner et al., 2000; Ruben et
al., 2008). There is less data regarding the rectum, but in a study by Schneider et al. (2005), the
risk for all organs was assumed to have a linear-exponential relationship to dose, and the organspecific exponential term was solved for based on epidemiological data from patients who
received radiotherapy for Hodgkin‟s disease. Their model for the colon (which includes the
rectum) has an inflection point at approximately 2 Gy.
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Figure 1.4 - Summary of the data showing the relationship between risk of second cancer and
dose from the A-bomb survivors and cancer survivors treated with radiotherapy (Ruben et al.,
2008). Reprinted from the International Journal of Radiation Oncology Biology Physics, 70,
Jeremy D. Ruben, Sidney Davis, Cherie Evans, Phillip Jones, Frank Gagliardi, Matthew
Haynes, Alistair Hunter, Risk of Second Malignant Neoplasms following VMAT and Proton
Arc Therapy for Prostate Cancer, 1532, 2008, with permission from Elsevier.
Using the risk models from the literature, Fontenot et al. (2009) predicted the risk of
SMN incidence (including fatal and non-fatal cancers) following both IMRT and proton
therapy for three prostate cancer patients (of small, medium, and large anatomical stature).
Specifically, the authors used detailed dosimetric information, including stray dose, and applied
risk models to calculate the risk to each organ. In order to cover the range of possible doseresponse relationships indicated by the data in the literature, they applied the LNT model
(NRC, 2006), the linear-exponential model, and the linear-plateau model. Furthermore, they
investigated high-dose (40 Sv) and low-dose (10 Sv) inflection points for the linear-exponential
and linear-plateau models, spanning the values reported in the literature. The specific quantities
they chose to describe risk were the excess relative risk (ERR), where

ERR

Rate in Exposed Population
1,
Rate in Unexpos ed Population

(1.1)

and the ratio of excess relative risk (RRR), where
RRR

ERR ProtonTherapy
ERR IMRT

.

(1.2)

They found, for all risk models considered, that the ERR of an SMN was less for proton therapy
than for IMRT (Fontenot et al., 2009) (Figure 1.5) within the uncertainties of the calculation
(Fontenot et al., 2010). It was also found that the in-field radiation in the bladder and rectum
had the largest impact on the ERR. Furthermore, passively scattered (RRR = 0.66) and scanned
(RRR = 0.56) proton therapies both conferred significantly lower predicted risk of SMN
incidence than IMRT.
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Figure 1.5 – The predicted risk of SMN incidence following IMRT and proton therapy of the
prostate from various risk models (Fontenot et al., 2009). It can be seen that the ERR of an
SMN following IMRT is consistently higher than following proton therapy, and by
approximately the same ratio (RRR). Reprinted from the International Journal of Radiation
Oncology Biology Physics, 74, Jonas D. Fontenot, Andrew K. Lee, Wayne D. Newhauser, Risk
of Secondary Malignant Neoplasms from Proton Therapy and Intensity-Modulated X-Ray
Therapy for Early-Stage Prostate Cancer, 621, 2009, with permission from Elsevier.
1.4. Statement of the Problem
The risk of SMN incidence following radiotherapy of the prostate is a potentially large
public health concern due to the large population of survivors. SMN risk has been estimated for
a few case studies following IMRT and proton therapy (Kry et al., 2005a; Schneider et al.,
2006; Schneider et al., 2007; Taddei et al., 2008; Fontenot et al., 2009; Bednarz et al., 2010);
however, VMAT and proton arc therapy are nascent and proposed modalities, respectively,
whose impact on risk of second cancer has not been previously reported. Both are new arc
modalities which distribute the therapeutic dose in a different way than their static counterparts.
In particular, while arc delivery achieves very conformal distributions in the target region, it
spreads lower dose over notably more tissue than static delivery (Kjaer-Kristoffersen et al.,
2009; Zhang et al., 2009). Thus, the effect of the differences between static beam and arc
delivery on predicted risk is not obvious and requires quantitative investigation.

16

It is also unknown how the margin size around the clinical target volume (CTV) to create
the planning target volume (PTV) affects predicted risk of an SMN for VMAT and proton arc
therapy. The required margin size depends on the internal motion, imaging, immobilization,
setup uncertainty, and the institution‟s experience (ICRU, 1999, 2007). With better
immobilization and image guided radiotherapy, margin sizes could be reduced. It is expected
that the predicted risk of an SMN will decrease with smaller margin sizes.
1.5. Hypothesis and Specific Aims
The hypothesis of this study is that the predicted RRR of SMN incidence in the bladder
and rectum 10 years following proton arc therapy relative to that following VMAT will be
less than one for prostate cancer for a typical patient exposed at age 60.
This hypothesis was tested through the following three specific aims:
Specific Aim 1: To predict the RRR of SMN incidence following proton arc therapy compared
to that following VMAT using calculated dose distributions combined with risk models from
the literature.
Specific Aim 2: To investigate the impact of uniform vs. variable beam weighting for proton
arc therapy based on various host and treatment factors, such as type of second cancer and
avoidance of a hip prosthesis, on the predicted RRR.
Specific Aim 3: To examine the sensitivity of the predicted ERR and RRR on the margin size
around the clinical target volume following proton arc therapy compared to that following
VMAT.
General Methodology
Three patients were selected for this study. For specific aim 1, treatment plans for both
VMAT and proton arc therapy were created for each patient, yielding 6 “nominal” treatment
plans. Then, the risk of SMN incidence was predicted for each treatment plan using three
different risk models: the linear-no-threshold, linear-exponential, and linear-plateau models.
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For specific aim 2, variable beam weighting was applied to one of the proton arc plans that was
created for specific aim 1, and its impact on risk of SMN incidence examined. Finally, for
specific aim 3, the margins around the CTV were varied, and new treatment plans were created
for each margin expansion for both VMAT and proton arc therapy. For each new margin plan,
the risk of an SMN was predicted to investigate the relationship between risk and margin size.

Chapter 2
Methods and Materials
This chapter describes the methods and materials used in this work, beginning with the
patient selection and volume contouring (2.1). Then, the methods for treatment planning and
therapeutic dose determination (2.2) is covered, with details pertaining to VMAT (2.2.1) and
proton arc therapy (2.2.2). Next, the estimation of stray dose (2.3) is discussed with specifics
regarding VMAT (2.3.1) and proton arc therapy (2.3.2). Subsequently, the method used to
predict risk of an SMN is discussed (2.4) with specifics regarding the LNT model (2.4.1) and
the alternate risk models (2.4.2), followed by an example calculation for each (2.4.3). Finally,
the methods section concludes with a review of the methods used for statistical analysis (2.4.4)
and uncertainty analysis (2.4.5), and a summary of the risk calculations performed (2.4.6).
2.1. Patient Selection and Contouring
We selected three patients who were previously studied by Fontenot et al. (2009) in a
comparison of the risk of SMN incidence following IMRT and parallel-opposed beam proton
therapy for prostate cancer. For their study, patient information was obtained, in accordance
with an institutional review board protocol, from electronic records of patients who were
treated at our institution for prostate cancer. A group of 72 patients who were treated in 2007
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were analyzed in order to identify patients who represented small, medium, and large patients
of the sample based on the range (90% distal dose fall-off) of the lateral proton beam to cover
the target volume (prostate, proximal seminal vesicles, and margin). The mean range of the
lateral beams was 24.7 cm, with a standard deviation of 1.2 cm. The mean range was
determined to be representative of a “medium” patient, and similarly the mean range plus and
minus 2σ of the mean range to be representative of a “large” and “small” patient, respectively.
A summary of the patients who most closely matched the mean, mean plus 2σ, and mean minus
2σ ranges is presented in Table 2.1.
Table 2.1 - Patient age at exposure, stage of cancer, and range of the proton beam for the
selected small, medium and large patients (Fontenot, 2008).
Patient Age
AdenoBeam
Patient
Calculated
at time of
carcinoma
Range
Size
Range (cm)
Treatment
stage
Formula
Small
60 yr
T2a
Mean - 2σ
22.3
Medium
56 yr
T2a
Mean
24.7
Mean +
Large
46 yr
T1c
27.0
2σ
The same organ and structure contours were used for the photon and proton treatment plans
for each patient in order to consistently compare the plans. These physician-approved contours
included the CTV, PTV, prostate, bladder, rectum, seminal vesicles, and femoral heads. In
addition, bladder wall, rectal wall, and various size additional PTV contours were created. The
bladder wall and rectal wall thicknesses were defined as 5 mm and 3 mm, respectively (Manieri
et al., 1998; Huh et al., 2003), using the automatic margin and Boolean operator tools in the
TPS. Slight manual edits were made when the organ wall was clearly visible and the
automatically created contour did not match the visible anatomy. The three patients in this
study were previously treated with proton therapy, and VMAT and proton arc therapy treatment
plans were retrospectively created for the purpose of this study. At the time of simulation,
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rectal balloons were used to immobilize the prostate and these immobilization devices were
visible on the CT images.
2.2. Treatment Planning and Therapeutic Dose Determination
All treatment plans were created using a commercial treatment planning system
(Eclipse, Varian Medical Systems, Palo Alto, CA). The MDACC clinical dose-volume
histogram (DVH) constraints (In-house dosimetry guideline, 2009) were used for planning and
evaluation of all plans (Table 2.2). Two treatment plans were created for each patient for
specific aim 1, one for each modality, and each of the resulting six nominal treatment plans
were reviewed, revised as needed, and approved by a board certified radiation oncologist.
Additional treatment plans were created for specific aims 2 and 3.
Table 2.2 - Dose volume histogram constraints used for VMAT and proton arc therapy
planning. „D‟ followed by a subscript number corresponds to the percent volume of the organ
receiving at least the listed dose constraint, where dose for VMAT is in units of Gy and dose
for proton arc therapy is in units of Gy (RBE). For example, D20 ≤ 70 means that 20% of the
volume should receive no more than 70 Gy or Gy (RBE).
Organ
DVH Constraints
Bladder

D20 ≤ 70 Gy or Gy (RBE)
D60 ≤ 40 Gy or Gy (RBE)
D50 ≤ 45 Gy or Gy (RBE)
D40 ≤ 60 Gy or Gy (RBE)

Rectum
D20 ≤ 70 Gy or Gy (RBE)
D15 ≤ 76 Gy or Gy (RBE)
D5 ≤ 80 Gy or Gy (RBE)
Femoral Heads

D15 ≤ 45 Gy or Gy (RBE)

For specific aim 1, the PTV was defined for all patients using margins specified by the
current MDACC standard-of-care, which is referred to as the nominal PTV. The CTV was
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expanded by 5 mm posteriorly and 7 mm in all other anatomical directions. Then, additional
PTVs with smaller and larger margins were created for the medium patient for specific aim 3.
All PTVs were created using the “margin for structure” tool to expand the CTV (Figure 2.1).

Figure 2.1 - Axial (left) and sagittal (right) CT slices showing the prostate (blue), PTV (red),
the rectum and contents (green), and the bladder and contents (yellow) for the nominal PTV
(top), a smaller PTV (middle), and a larger PTV (bottom). Notice the decreased amount of
normal tissue encompassed within the smaller PTV and the increased amount of normal tissue
encompassed within the larger PTV.
In this study the majority of the additional PTVs were smaller than the nominal PTV
because it is likely that future improvements in immobilization and imaging technologies will
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enable smaller margins, i.e. a reduction from our current nominal PTV margins. We used
margin expansions ranging from 0 mm (the theoretical limit) to 6 mm posteriorly and 8 mm in
all other anatomical directions. A detailed list of all PTV margins used in this study can be
found in Table 2.3.
Table 2.3 – Variable CTV expansion margins used to create different PTVs and their
differences from the nominal expansions. “Else” refers to all anatomical directions other than
posterior.
Posterior
Else
Posterior
Else
Difference Difference
Plan
Expansion Expansion
from
from
Index
(mm)
(mm)
Nominal
Nominal Comment
(mm)
(mm)
5
7
0
0
Nominal
1
0
0
-5
-7
Smallest
2
0
2
-5
-5
3
2
4
-3
-3
4
3
5
-2
-2
5
4
6
-1
-1
6
6
8
1
1
Largest
2.2.1. Volumetric Modulated Arc Therapy
The Eclipse TPS (Version 8.6) was used for VMAT planning. Dose was computed with the
Anisotropic Analytical Algorithm (AAA) (Van Esch et al., 2006) with heterogeneity
corrections and a 2.5 mm calculation grid. The TPS was commissioned for clinical use at our
institution (R. M. Howell, pers. comm.). All of the VMAT plans were planned with 6 MV
photons to a prescribed mean dose of 76 Gy to the PTV in 38 fractions. Then, in accordance
with the standard-of-care, a normalization was applied to provide coverage of the 76 Gy
isodose line around the PTV, 96.4% was the largest normalization required, and, in order for
the prescription dose to be a control in this study, the normalization of 96.4% was applied to all
plans. The photon absorbed dose in gray is equal to the equivalent dose in sieverts due to a
radiation weighting factor of 1 for photons (ICRP 1990).
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VMAT treatment planning for this study was consistent with the MDACC clinical practice
(R. M. Howell, pers. comm.). Each treatment plan had two overlapping 220 degree arcs, each
subtending the angle from 110 to 250 degrees (one clockwise and one counter clockwise arc).
Two arcs double the possible number of control points and allows a higher degree of
modulation, and the 60 degree gap minimizes entrance dose to the rectum (Figure 2.2). The
collimator rotation was set to 30 degrees for the first arc and 330 degrees for the second to
minimize overlap of inter-leaf leakage from the two arcs. In addition, for beam optimization
purposes, avoidance structures were used to further conform the dose. For example, constraints
were applied to a rectal avoidance volume that included the posterior portion of the rectum.

clockwise arc
counterclockwise arc
Figure 2.2 – Illustration of the two arcs used for VMAT treatment planning. It can be seen that
the angle and modulation (orange lines inside yellow field lines, which are visible on the
counterclockwise arc) spare the rectum (green) of entrance dose.
For specific aim 1, treatment plans were optimized for the nominal PTV for the small,
medium, and large patients. For specific aim 3, additional treatment plans were optimized for
each of the alternate PTVs for the medium patient. The same objectives and constraints were
used for both the nominal and alternate PTVs (Table 2.3). Therefore, the main difference
between these treatment plans was the volume of the high-dose region.
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2.2.2. Proton Arc Therapy
The Eclipse TPS (Version 8.9) was used for proton arc therapy planning. Dose was
computed with a proton pencil beam algorithm (Schaffner, 2008) with heterogeneity
corrections and a 2.5 mm calculation grid. The TPS was previously configured and tested for
proton radiotherapy at our institution (Newhauser et al., 2007b). The prescribed mean dose was
76 Gy (RBE) to the PTV in 38 fractions. Then, similarly to the VMAT plans (section 2.2.1), all
plans were normalized to 96.4%, resulting in a mean dose of 78.8 Gy (RBE) to the PTV.
Treatment planning techniques for photon arc therapies are approximated with static treatment
beams (Mackie et al., 1993; Yu, 1995; Otto, 2008; Bzdusek et al., 2009). In the same way, we
approximated proton arc delivery in the TPS with static, discrete treatment beams, each
representing an arc segment centered at the beam angle (Flynn et al., 2007).
In order to determine the number of static proton beams required for a reasonable
approximation in the treatment planning of arc delivery, treatment plans with 4, 6, 8, 12, 16, 24,
and 32 equally spaced gantry angles were investigated. Because the dose distribution in a 4beam plan with angles of 0, 90, 180 and 270 degrees depended on starting angle for a coarse
beam resolution, a second 4-beam treatment plan was created with beam angles of 45, 135,
225, and 315 degrees. The mean doses to the bladder (and contents), bladder wall, rectum (and
contents), rectal wall, femoral heads, and normal tissue of the pelvis were plotted vs. the
number of beams to test for dosimetric sensitivity to the choice of beam number in
approximating arc plans.
Based on the results of the above experiment (results are described more fully in section
3.1.2), we found that sixteen beams were adequate to approximate arc therapy for the purposes
this study. The sixteen beams were equally spaced at the angles of 22.5, 45, 67.5, 90, 112.5,
135, 157.5, 180, 202.5, 225, 247.5, 270, 292.5, 315, 337.5, and 360 degrees around the patient,
where each static beam approximated 22.5 degrees of arc delivery.
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Unlike the procedure used for VMAT treatment planning, the PTV was not explicitly used
to design the proton treatment plans. Instead, margins around the CTV were selected to provide
conservative coverage, which consequently encompassed the PTV within a high dose region. A
generic PTV is not suitable as the primary planning volume for proton therapy because it is a
geometrical concept that assumes the “static dose cloud approximation” (Unkelbach et al.,
2009). Under this approximation, it is assumed that the location in space and shape of the dose
distribution are virtually unaffected by changes in the anatomy, e.g. setup errors or tumor
motion. This approximation is appropriate for photon therapy, but not for proton therapy where
changes in anatomy or positioning could cause range errors (Urie et al., 1984; Zhang et al.,
2007; Lomax, 2008; Unkelbach et al., 2009). The ideal margins around the CTV are
determined based on factors like beam range, SOBP width, and uncertainties in delivery such
as motion (Moyers et al., 2001; Moyers and Miller, 2003; ICRU, 2007). A diagram of how
proton therapy treatment margins are usually defined is shown in Figure 2.3.
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Figure 2.3 - Margins defined in treatment planning for proton therapy of the prostate. Proximal
and distal margins are defined as the distance from the CTV to the edge of the SOBP. Lateral
margins are defined as the distance from the CTV to the lateral field edge The labels anterior
and posterior could apply to lateral, proximal, or distal margins, depending on beam direction.
For example, an anterior-posterior beam would have a posterior distal margin at the end of
range of the beam. The box defined by the SOBP and the field edges is the high-dose region,
which should at least encompass the PTV.
For all gantry angles, the margins, border smoothing, and compensator smearing (Urie et
al., 1984; Urie et al., 1986) were determined based on techniques that were the standard-of-care
for lateral opposed proton therapy for prostate cancer at MDACC in 2010 (In-house dosimetry
guideline, 2009). The lateral margin from the CTV was set to 1.7 cm, and reduced by 0.2 cm
posteriorly to 1.5 cm to provide rectal sparing for the 6 lateral-most beams (67.5, 90, 112.5,
247.5, 270, and 292.5 degrees). Then, a “test beam” was applied to each field to cover the CTV
with zero margins, and the SOBP and range of each “test beam” were used to calculate the
treatment parameters. The distal margins were calculated as 3 mm plus 3.5% of the range, and
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the proximal margins were calculated as 3 mm plus 3.5% of the range minus the SOBP width
(Moyers et al., 2001). The border smoothing was set to the typically used standard-of-care
value of 1 cm. The compensator smearing was found by taking the quadratic sum of 3% of the
range and the sum of setup and motion uncertainty. Anterior-posterior (AP) and posterioranterior (PA) beams are not part of the standard-of-care at our institution. However, it was
desired to replicate the rectal sparing provided by the 0.2 cm posterior reduction in the lateral
margins in the AP and PA beams. In order to provide this sparing, 0.2 cm was subtracted from
the posterior margins of the 6 AP- and PA–most beams (22.5, 157.5, 180, 202.5, 337.5, and
360 degrees). Then, the margins, border smoothing, and compensator smearing were applied in
the TPS to calculate the final treatment beams (which resulted in a final range and SOBP for
each beam). Following this method, treatment plans with uniform beam weighting were created
for the small, medium, and large patient for specific aim 1, and were defined as the nominal
proton arc treatment plans for these patients.
Specific aim 2 investigated the dosimetric impact of variable beam weighting for the proton
arc therapy plan for the medium patient. The ERR of SMN incidence attributed to the
therapeutic dose from each individual beam was determined using an LNT risk model (section
2.4) and minimized using a gradient search algorithm (Microsoft Office Excel 2003, Microsoft
Corporation, Redmond, WA). Corresponding contralateral beams (Figure 2.4) had nearly
identical risk of an SMN due to anatomical symmetry of the pelvis (for example, 45 and 315
degrees). Because of this symmetry, the risks from contralateral beams were averaged then
minimized as a pair of right and left beams with equal weights. The objective function to be
minimized was based on the risk of an SMN of the bladder, rectum, or a combination of the
two. However, because the AP and PA beams were on the sagittal axis, these two beams did
not require a contralateral pair.
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Figure 2.4 – Illustration of beam pairs. Paired beams are denoted by the same color line.
Beams were paired because they contributed approximately the same risk of SMN due to the
symmetry of the pelvis. Because the AP (0/360 degrees) and PA (180 degrees) beams were on
the sagittal axis, they were not paired.
Constraints on the optimization ensured that the maximum and minimum weights of each
beam were within the mechanical and radiation limitations of the treatment unit (Table 2.4).
The dynamic range of the proton gantry rotation speed was measured to be a factor of 10,
ranging from 0.1 rpm to 1 rpm. The dynamic range of the dose rate spanned 0.2 Gy/min to 2
Gy/min. A proton therapy MLC would be required to routinely deliver the proton arc therapy
plans described in this work, and the maximum MLC leaf speed was estimated from the
literature to be 3 cm/s (Wijesooriya et al., 2005). The maximum leaf speed required for the
nominal proton arc treatment plan was determined by measuring the distance from the cranialcaudal axis at isocenter in 0.5 cm intervals for each aperture, finding the maximum difference
in distance between consecutive static apertures, then dividing the distance by the minimum
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time per beam. It was found that the maximum leaf speed required was 0.75 cm/s (ignoring
acceleration requirements, which were deemed of secondary importance compared to the other
approximations). Therefore, it was not necessary to explicitly constrain beam weighting based
on MLC leaf operating characteristics. The treatment time was constrained at 5 minutes or less
for patient comfort, and facility throughput and efficiency. The constraints in this work were
estimated for the purpose of theoretically testing the feasibility of proton arc delivery. In
general, these limitations are facility- and machine-specific.
Table 2.4 - Constraints placed upon the optimization algorithm to determine beam weighting.

Sets of optimal beam weights were separately determined for the following objectives:
minimize the total of risk of an SMN in the bladder and the rectum, the bladder only, and the
rectum only. The latter two cases are mainly for illustrative purposes, but could have
hypothetical clinical implications. For example, in the unusual case that a patient has had a
cystectomy or proctectomy, it would be impossible to induce an SMN in an organ that has been
removed.
An additional special case was considered for specific aim 3. A treatment plan with a set of
non-uniform beam weights optimized to minimize the risk of second cancers in the bladder and
rectum was generated for a patient with a prosthetic hip. For this patient, the beams traversing
through the prosthesis on the ipsilateral side of the patient (67.5, 90, and 112.5 degrees) were
disallowed due to complications with treating through a large, metal implant including range
limitations and CT artifacts (Newhauser et al., 2008), then the optimization was performed as
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before. Due to the asymmetry of the anatomy and limitations on allowed beam angles, beams
were not mirrored during optimization.
A summary of the four optimization objectives for which optimized treatment plans were
created for specific aim 2 is provided in Table 2.5.
Table 2.5 – Objectives and constraints for specific aim 2 for which optimal beam weighting
was found using gradient search optimization. Then, the beam weights were applied to the
medium patient‟s nominal treatment plan to create risk-minimized plans for each objective.
Constraints and Objectives Taken into Account
Minimize Risk of
Minimize Risk of
Forbidden Angles
Objective Index
SMN of Bladder
SMN of Rectum
[degrees]
1
Constrained
Constrained
2
Constrained
3
Constrained
4
Constrained
Constrained
67.5, 90, 112.5
Specific aim 3 investigated the impact of margin size on predicted risk. Therefore, proton
arc treatment plans were created for the medium patient with varying margins around the CTV,
each with a corresponding VMAT treatment plan as described in section 2.2.1. However, as
mentioned previously, there are subtleties regarding the comparison of margins from photon
and proton plans due to differences in planning procedure (Moyers et al., 2001; Moyers and
Miller, 2003; ICRU, 2007). Photon plans were directly planned to the PTV, while proton plans
were planned to the CTV with margins that did not exactly correspond to expansions to a PTV
(Figure 2.3).
As mentioned above, the proton arc plans were not explicitly planned to the PTV.
Therefore, in order to create plans for specific aim 3, the differences in PTV size from nominal
(last two columns in Table 2.3) were applied to the nominal proximal, distal, and lateral
margins around the CTV to produce plans that were appropriate for the different sized PTVs.
Figure 2.5 illustrates this method, which corresponds to the middle section of the diagram in
Figure 2.3. The resulting treatment margins and compensator smearing for the treatment plans
created for specific aim 3 are listed in Tables 2.6 and 2.7.
30

Figure 2.5 - Diagram showing the transformation applied to margins to cover a different sized
PTV. Here, the PTV below is 3 mm smaller. Therefore, 3 mm is subtracted from all margins to
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provide the appropriate field size and SOBP to at least encompass the smaller PTV (diagram
not to scale).
Table 2.6 - Compensator smearing and proximal and distal margins (in cm) from the CTV for
the proton arc plans. Plan indices correspond to those of the expansions listed in Table 2.3. The
beams angles are in units of degrees.

Table 2.7 - Lateral margins (in cm) from the CTV for the proton arc plans. Plan indices
correspond to those of the expansion margins listed in Table 2.3. “Rectal Side” refers to the
posterior margin, which encroaches on the rectum. The beam angles are in units of degrees.

2.3. Stray Dose Estimation
2.3.1. Volumetric Modulated Arc Therapy
Commercial TPSs accurately calculate therapeutic dose (Aspradakis et al., 2003), but
underestimate stray radiation (Howell et al., 2010a; Howell et al., 2010b). Howell et al. (2010a;
2010b) reported that the TPS used in this study underestimated the stray dose by an average of
40% ± 20% for regions where the reported dose was less that 5% of the prescribed dose. In that
study, they found that the worst underestimation occurred farthest from the field edge (i.e. very
low isodose regions).
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Therefore, in this study, to more accurately approximate stray radiation, we increased the
doses that were less than 5% of the prescription dose. This was accomplished by multiplying
the doses in the differential dose-volume histogram (DVH) ranging from 0% to 5% of the
prescription dose by 1.4. This procedure was conservative in that the average distance from the
field edge in our study exceeded that reported by Howell et al. Then, the risk was calculated
using the modified DVH.
2.3.2. Proton Arc Therapy
Because the commercial TPSs for proton therapy do not predict stray neutron dose, an
in-house Monte Carlo method was used to predict these values. Monte Carlo methods have
been used in the past to estimate stray doses for proton therapy (Agosteo et al., 1998; Schneider
et al., 2002; Paganetti et al., 2004; Fontenot et al., 2005a; Polf and Newhauser, 2005; Jiang et
al., 2005; Herault et al., 2005; Tayama et al., 2006b; Zheng et al., 2007a; Zheng et al., 2007b;
Zheng et al., 2008b; Moyers et al., 2008a; Zacharatou Jarlskog et al., 2008; Taddei et al., 2008;
Fontenot et al., 2008; Fontenot et al., 2009; Newhauser et al., 2009a; Taddei et al., 2009b;
Bednarz et al., 2009; Fontenot et al., 2010; Zhang et al., 2010; Taddei et al., 2010a; Taddei et
al., 2010b; Taddei et al., 2010c). The Monte Carlo code MCNPX (Monte Carlo N Particle
eXtended) (Waters et al., 2007; Pelowitz, 2007) has been used extensively by our research
group (Newhauser et al., 2007b) and was chosen for this work.
Monte Carlo simulations were completed to estimate the stray neutron dose for the proton
arc therapy treatment plan for the medium patient. The process is reviewed here, and further
details can be found in the literature (Newhauser et al., 2007b; Fontenot et al., 2008; Zheng et
al., 2008a; Fontenot, 2008). We used an in-house code that converts patient CT and other
treatment plan information into MCNPX input files, runs MCNPX simulations with version
2.7c of the code, then converts the output into Digital Imaging and Communications in
Medicine (DICOM) files that can be re-imported into the TPS for visualization and analysis.
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For these simulations, the entire proton nozzle was simulated (Newhauser et al., 2007a), and
the patient CT dataset was used as the voxelized phantom on which the dose was calculated
using F6 tallies. Once the simulated dose distributions were re-imported in to the TPS, mean
neutron doses to the bladder wall and rectal wall were computed and recorded.
Because neutrons have a different RBE for carcinogenesis than photons, a radiation
weighting factor must be applied to convert absorbed dose to equivalent dose. The equation
describing the relationship between absorbed dose and equivalent dose is

H

wR D ,

(2.1)

where H is the equivalent dose, wR is the radiation weighting factor for neutrons, and D is the
absorbed dose. Publication 92 of the International Commission on Radiological Protection
(ICRP) (2003) recommends a continuous function for the weighting factor of neutrons based on
neutron energy (Figure 2.6), with a maximum of approximately 20 at 1 MeV.
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Figure 2.6 - Radiation weighting factor (wR) for neutrons vs. neutron energy (reprinted with
permission) (ICRP, 2003).
Because the neutron spectra incident upon each organ are unique, wR values are also
unique to each organ. These were determined by Fontenot et al. (2008; 2008; 2009) for a
parallel-opposed proton therapy treatment of the prostate (Table 2.8) for the same three patients
as studied in this work. In order to be conservative, the largest values of wR of the three
patients were used for all three patients in our study. Because of the uncertainty in determining

wR values (Kellerer et al., 2006; Hall, 2007; Fontenot, 2008; Fontenot et al., 2010), factors of
0.5, 2, and 5 were applied to the ICRP values for sensitivity analyses (Table 2.8), where a value
of 5 corresponds to a maximum neutron radiation weighting factor of approximately 100. The
sensitivity of risk predictions to uncertainty in the radiation weighting factor was evaluated
using the medium patient‟s nominal treatment plan.
Table 2.8 – Mean neutron radiation weighting factors for the bladder and rectum for a parallelopposed proton therapy treatment of the prostate determined in the work of Fontenot et al.
(2008; 2008; 2009). For sensitivity analysis, the wR values were modulated by factors of 0.5, 2
and 5.
Organ
0.5* wR
2* wR
5* wR
wR
Bladder
7.36
3.68
14.72
36.80
Rectum
6.94
3.47
13.88
34.70
Then, the total equivalent dose for each dose-bin of the bladder wall and rectal wall from
a proton therapy treatment for prostate cancer was found with the equation
H total

1.1 Dabsorbed

H stray

(2.2)

where Htotal is equal to the total equivalent dose in sieverts for the dose-bin, 1.1 is the
recommended generic RBE value for protons (section 1.2.2) to convert to Gy (RBE), Dabsorbed is
the absorbed therapeutic proton dose in gray, and Hstray is the stray equivalent dose (equation
2.1).
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The stray doses for the small and large patients in this study were approximated as the stray
doses estimated by Fontenot et al (2008) using MCNPX. In their study, the stray dose from
parallel-opposed beam proton therapy was simulated for the same prostate cancer patients as
used in this work. The total stray dose from parallel-opposed beam proton therapy of the
prostate apparently provides a conservative estimate of the total stray dose from proton arc
therapy of the prostate (Sengbusch et al., 2009). Neutron production increases as proton energy
increases (Zheng et al., 2008a) and the highest beam energies in a proton arc therapy treatment
plan occur at the lateral angles. Therefore, the lower energy protons from other angles produce
fewer neutrons and contribute to a lower overall stray dose. However, the beam arrangement is
uniformly distributed around the patient for our study, which could produce a different
distribution of neutrons throughout the body. Despite the discrepancies in the beam
arrangement, this was determined to be a reasonable estimate of neutron dose for this study.
2.4. Risk Prediction
Unlike previous studies (Taddei et al., 2008; Fontenot et al., 2009), the risk to the bladder
and rectum were found using organ wall contours instead of the conventional whole organ
contour, including contents. The motivation behind our choice is that the contents of those
organs will be excreted from the body and therefore do not have carcinogenic capabilities.
Consequently, for detailed dosimetric studies predicting carcinogenic risk, it naturally follows
to delineate organs as solely the organ tissue and to exclude the contents.
2.4.1. Linear-No-Threshold Risk Model
The BEIR VII report (NRC, 2006) provides a method for predicting risk of radiogenic
cancers and assumes an LNT relationship of risk of second cancer and dose. The quantity of
excess relative risk (ERR) was chosen as the metric to express the risk of incidence of an SMN
for this work. ERR is defined as
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ERR

Rexposed

1,

Runexposed

(2.3)

where Rexposed is the rate of the exposed population, Runexposed is the rate of the unexposed
population. The risk coefficient of

ERR
(Sv-1) is calculated with the following equation:
H
ERR
H

M

e e*

a
60

,

(2.4)

where e* is equal to the age at exposure in years minus 30 when the age at exposure is less than
30 years and equal to zero when the age at exposure is greater than 30 years; a is attained age
(years);

M

is the age-specific, and organ-specific instantaneous ERR/Sv value for males; γ

accounts for the per-decade increase in age at exposure over the range of zero to 30 years, and
η represents the exponent of attained age (NRC, 2006). From the information in BEIR VII and
equation 2.4, risk coefficients were derived to be 0.51 ERR/Sv for the colon and 0.40 ERR/Sv
for the bladder for the three patients studied (Fontenot, 2008). In addition, to separate the
rectum from the colon, relative mass-fractions from Publication 89 of the ICRP (2002) were
applied; 0.2 for the rectum and 0.8 for the colon.
Then, the ERR for each dose-bin, i, from the differential DVH was found by applying the
risk coefficient to the equivalent dose of each dose-bin,
ERRT

where

msubregion
mT

msubregion
i

mT

Vi
VT

Hi

ERR
H

,

(2.5)

T

is the fractional mass of the subregion compared to the total mass of the organ

(0.2 for the rectum, 1 for the bladder), Vi is the volume of the dose-bin (cm3), VT is total the
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volume of the tissue (cm3), Hi is the total equivalent dose (Sv) of the dose-bin, and

ERR
H

is
T

the tissue-specific risk coefficient derived from the equation 2.4 above (Sv-1).
Next, the ERRT

i

was summed over n dose-bins to find the ERR for a given tissue:

n

ERRT i .

ERRT

(2.6)

i 1

It should also be noted that, for the LNT model, multiplying the risk coefficient by the
tissue mean equivalent dose is the same as equation and 2.6 because of the linear relationship
of risk and dose. This concept is described mathematically in equation 2.7,

msubregion

n

ERRT

ERRT

i

HT

mT

i 1

ERR
H

,

(2.7)

T

where, HT is the mean equivalent dose of the tissue.
Finally, the total ERR for the patient was obtained from the sum over m tissue ERRs (m=2
for our study: bladder and rectum),
m

ERR

ERRT

j

.

(2.8)

j 1

Once the ERR was determined (regardless of risk model), the ratio of excess relative risk
(RRR) was calculated by
RRR

ERR ProtonArc
.
ERR VMAT

(2.9)

According to this definition, an RRR less than one indicates a lower risk of an SMN following
proton arc therapy and an RRR greater than one indicates a lower risk of an SMN following
VMAT.
2.4.2. Alternate High Dose Risk Models
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The LNT relationship of the BEIR VII report is appropriate to predict radiogenic cancer
risk for low doses up to a few sieverts (NCRP, 1993; Hall and Wuu, 2003; NRC, 2006), but the
relationship between dose and risk is less well understood at higher doses. As discussed in
section 1.3 and following the approach of Fontenot et al. (2008; 2009), the linear-exponential
and linear-plateau models are proposed alternatives to the LNT model that account for cell
sterilization. These models decrease or plateau, respectively, beyond a given equivalent dose
which ranges from approximately 10 Sv to 40 Sv in the literature. The forms of the alternate
risk models were similar to the work by Schneider et al. (2005; 2006; 2007) and were
generated and applied by Fontenot et al. (2008; 2009). Both dose levels for inflection of the
risk models were investigated in this work and will be denoted as the name of the risk model
with a “-10” or “-40” suffix, e.g., “linear-exponential-10”.
The linear-exponential model of ERR for a dose-bin (ERRT)i was calculated with the
equation,
ERRT

where

ERR
H

msubregion
i

mT

Vi
VT

0

ERR
H

Hi e

T Hi

,

(2.10)

T

0

is the organ-specific LNT risk model from BEIR-VII, Hi is the tissue-specific
T

equivalent dose for the dose-bin, and αT is the tissue specific parameter that accounts for cell
sterilization. Likewise, the linear-plateau excess relative risk for a dose-bin is given by

ERRT

msubregion
i

mT

Vi
VT

ERR
H

0

T

1 e

T Hi

,

(2.11)

T
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where the variables correspond to those in equation 2.10. The values for

ERR
H

0

and αT for
T

the bladder and rectum were computed by Fontenot et al. (2008) and are listed in Table 2.9,
below.
Table 2.9 - Risk model parameters for the linear-exponential and linear-plateau models for the
bladder and rectum in Sv-1 (Fontenot, 2008).
Bladder
Rectum
Risk Model
Linear-exponential-10
Linear-exponential-40
Linear-plateau-10
Linear-plateau-40

ERR
H
0.49
0.46
0.51
0.47

0

αT
T

0.090
0.025
0.250
0.068

ERR
H
0.61
0.57
0.65
0.58

0

αT
T

0.090
0.025
0.250
0.068

Then, the RRRs for the linear-exponential and linear-plateau models were found using the
same method as for the LNT model. First the ERRdb was summed over all dose-bins (equation
2.6), then the ERRT was summed over all tissues (equation 2.8), and finally the RRR was found
by taking the ratio of the ERRProtonArc to ERRVMAT (equation 2.9).
To illustrate the behavior of risk as a function of dose, Figures 2.7 and 2.8 plot the predicted
risk for incidence of SMN in the bladder and rectum, respectively.
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Figure 2.7 - The LNT, linear-exponential, and linear-plateau risk models used to predict ERR
of SMN incidence of the bladder (Fontenot et al., 2009). Volume-weighting for the fractional
V
volume of a specific dose-bin, i , has been set to 1 for this figure.
VT

41

Figure 2.8 - The LNT, linear-exponential, and linear-plateau risk models used to predict ERR
of SMN incidence of the rectum (Fontenot et al., 2009). Volume-weighting for the fractional
V
volume of a specific dose-bin, i , has been set to 1 for this figure. It can be seen that,
VT
partially due to the 0.2 mass-weight for the rectum, the ERR per Sv is less for the rectum than
for the bladder.
2.4.3. Example Risk Calculations
To clarify the process of risk calculation, an example for both the LNT and an alternate risk
model are provided below. First, the risk of an SMN of the bladder (wall) for the medium
patient following VMAT was found using the LNT model. In this case, the mean dose to the
bladder wall was 16.8 Sv (see sections 3.1.1 and 3.2.1), and the organ-specific, patient-specific
risk coefficient for the bladder was 0.4 Sv-1 (section 2.4.1). Therefore, following equation 2.7,
the LNT ERR for the bladder was given by
16.8 Sv

0.4 Sv

1

6.7 .

(2.12)
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The second example calculation, shown below, describes the prediction of the risk of
SMN incidence in the rectum (wall) for the medium patient following proton arc therapy for
the linear-exponential-10 risk model. The differential DVH for the tissue of interest was
required for this calculation, and was exported from the treatment planning system into a
spreadsheet. A graph of the differential DVH for the rectal wall was shown below in dark blue
in Figure 2.9. After the differential DVH was obtained, the stray dose was added to every dosebin. Then, equation 2.10 was applied to each dose-bin to obtain the differential excess relative
risk contributed by each dose-bin (Figure 2.9).

Figure 2.9 - Calculated differential DVH and (ERRT)i for the rectum for the nominal proton arc
therapy plan for the medium patient.

Finally, the differential risks were summed to yield the total risk for the tissue. Combining
equations 2.6 and 2.10, this process can be expressed as
n

ERRT

0.2

i
i 1

Vi
0.61 H i e
33

0.09 H i

0.19 ,

(2.13)
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where the sum was over all dose-bins, the 0.2 weighting factor is the

msubregion
mT

for the rectum,

Vi is the volume of the dose-bin in cm3, 33 is the VT of the rectal wall in cm3, 0.61 is the
ERR
H

0

for the linear-exponential-10 model for the rectum (Sv-1), Hi is the equivalent dose for
T

the dose-bin (Sv), and 0.09 is αT for the rectum (Sv-1) (Table 2.9).

2.4.4. Statistical Analysis
Due to time constraints on the length of this thesis project, the sample size for this work
was limited to three patients. Despite the limited sample size, two statistical tests were chosen
to compare the proton arc therapy and VMAT risk estimates: the sign test and the t-test
(Rosner, 2006). The objectives of the tests in this work were mainly educational. However,
these tests would be appropriate for a larger sample size, e.g., a future work. The software
package StatXact® version 7.0 from Cytel Studio (Cambridge, MA) was used for both
statistical tests.
The sign test is a nonparametric test that determines whether two samples are from the
same distribution but ignores the magnitude of the differences, which makes it insensitive to
outliers. Because of the small sample size, the exact sign test was performed. For our purposes,
the quantity of interest was RRR and the value of interest was one (meaning equal risk
following proton arc therapy and VMAT), and each RRR was defined as “+” if it was greater
than one and “–“ if was less than one. The null hypothesis was H0: P(+) ≥ P(–) and the alternate
hypothesis was H1: P(+) < P(–), where P(±) is the probability of a + or –, respectively. The test
statistic T is found, which is the total number of –‟s (RRR < 1). Then, n was defined to be the
total number of +‟s and –‟s, excluding ties. Next, t is found using the equation

t

1
n w n
2

1
2

,

(2.14)
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where wα is the 95th percentile of the w distribution for a one-sided significance level (α) of
0.05 (α is also the probability of a falsely rejecting the null hypothesis). Finally, H0 was
rejected at the level of α if T is greater than or equal to n-t (Conover, 1980).
The t-test is a parametric test that determines whether the mean of a sample distribution is
the same as the population mean. It should be noted that the t-test assumes a t-distribution for
the sample mean, which may not be assumable for a sample size of three, given the underlying
distribution of ERR. Regardless of the small sample size, it was decided that performing the ttest was of pedagogical value. In this case, to test null hypothesis H0: RRR ≥ 1 vs. the alternate
hypothesis: H1: RRR < 1, with a one-sided significance level α of 0.05, the test statistic t was
computed (Rosner, 2006) according to
t

x

0

s

,

(2.15)

n

where x is the sample mean (RRR), μ0 is the expected or population mean (1), s is the sample
standard deviation, and n is the sample size. The null hypothesis was rejected if t < tn-1,1-α,
where tn-1,1-α is the 5th percentile of the t distribution with n-1 degrees of freedom for a onesided test.
2.4.5. Uncertainty Analysis
In order to estimate the uncertainty associated with the prediction of the mean RRR, error
propagation was performed. A derivation of the formula for uncertainty in RRR for a patient
was reported by Fontenot et al. (2008; 2010) and was adapted for this work. One of the
differences in our formula is that the uncertainty in therapeutic and stray dose for VMAT
(analogous to IMRT in the work of Fontenot et al.) was combined into one factor due the
method utilized for stray dose estimation. Another difference is that there is a term for the
uncertainty in the wR added in quadrature. Additionally, our error propagation is explicitly for
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the mean RRR, in order to incorporate the covariance from the correlations between the
modalities. Finally, it was found that the uncertainty in risk model was asymmetric when the
LNT model was assumed as the baseline risk model. Therefore, a term for uncertainty in the
risk model was added in quadrature, but only to the negative side. This resulted in an
asymmetrical overall relative uncertainty in the mean RRR:
2

2
2

RRR

T 1

D1

2

ERR
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2

p 1
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(2.16b)

is the relative uncertainty in the mean RRR, and the quantity σ

represents one standard deviation (therefore a 68% confidence interval). The outermost sum is
over the 3 patients (p), and the inner sums are over the two tissues (T) - the bladder and the
rectum. The subscript V denotes VMAT and the subscript P denotes proton arc therapy. ERR1
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is the excess relative risk from primary radiation,

D1

D1

is the relative uncertainty in the

therapeutic dose from the treatment planning system for proton arc therapy and the total
uncertainty in the VMAT dose, ERR 2 is the excess relative risk from the stray radiation,
D2

D2

is the relative uncertainty in the stray dose, and ERRT is the total excess relative risk

for a given tissue. The

D1

D1

from the VMAT plan was estimated using the quadratic sum of

the relative uncertainty in the therapeutic dose from the treatment planning system and the
uncertainty in the stray dose correction method (section 3.2.1). The two terms

RRR

RRR

RRR

RRR

and
wR

are the relative uncertainty in the mean RRR contributed from the uncertainty in the
RM

wR and risk model, respectively. Both of these quantities were determined with a sensitivity
analysis to evaluate their effect on RRR, which is why they are relative to RRR and added in
RRR

quadrature to the rest of the equation.

RRR

was estimated by assuming the 95%
wR

confidence interval of the wR was 0.5* wR to 5* wR (Table 2.8) for each patient and dividing
the range in resulting mean RRR by 2 to find 2σ. Then, 2σ was divided by 2 to obtain the
numerator in the uncertainty term.

RRR

RRR

only contributed to the negative overall
RM

uncertainty term (2.16b). This term was also found with a sensitivity analysis, where the range
in mean RRR values from the risk models studied in this work was assumed to be one σ of the
distribution of RRR from uncertainty in the risk model. The last term accounts for the
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covariance, which, in this case, reduces the relative uncertainty in the mean RRR because
correlations in the error of the terms used in the calculation of the mean RRR. The covariance
was calculated using the equation:

1
n

ERRV ERRP

n

ERRVi

ERR Vi ERR Pi

ERR Pi ,

(2.17)

i 1

where n is the number of patients (3 for this study), and ERR denotes the mean value (Taylor,
1982).
In addition to propagating the uncertainty for the mean RRR, the uncertainty was
propagated for two specific cases. First, the uncertainty was propagated for each patient
individually according to the equations:
2

2

RRR

ERR

D1

T 1

RRR

2
1

D1

ERR12

2

2

2
T 1

ERR

D1

2

2

2

D1

D2

2
2

D2

2
RRR

2

2

ERRT

RRR

ERRT

T 1

wR

T 1

V

P

(2.18a)

2

2

ERR12

2
RRR

RRR

T 1

2

2
2
1

ERR

D1

D1

T 1
2

2

D1

D1

ERR

D2

D2

2
RRR

2

2

ERRT
T 1

2
2
2

RRR

ERRT

2
RRR

wR

RRR

RM

T 1

V

P

(2.18b)
where the variables correspond to equations 2.16a and 2.16b, but are for each patient instead of
the mean. Second, the uncertainty was propagated for the mean RRR (according to equations
2

2.16a and 2.16b) without the

RRR

RRR

and the covariance term.
wR
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2.4.6. Summary of Risk Calculations
In order to clarify and summarize the methods for this work, the various combinations of
variables studied are organized below in Tables 2.10 and 2.11.
Table 2.10 - Summary of variables and their corresponding specific aim.
Proton
Patient
Modality
Goal
Risk Model
Arc Beam
Model
Studied
Weighting
Small
Linear-no-threshold
Baseline
VMAT and
Medium
Linear-no-threshold
Uniform
LNT RRR
Proton Arc
Estimate
Large
Linear-no-threshold
Small,
Med, and
Linear-exponential-10
Large
Small,
Med, and
Linear-exponential-40
Sensitivity of
Large
VMAT and
Uniform
RRR to Risk
Proton Arc
Small,
Model
Med, and
Linear-plateau-10
Large
Small,
Med, and
Linear-plateau-40
Large
Sensitivity of
RRR to
Medium
Linear-no-threshold
Proton Arc
Uniform
Neutron w R
Sensitivity of
RRR to
Medium
Linear-no-threshold
Proton Arc
NonBeam
uniform
Weighting
Linear-no-threshold
Linear-exponential-10
Sensitivity of
VMAT and
Medium
Linear-exponential-40
Uniform
RRR to
Proton Arc
Margin Size
Linear-plateau-10
Linear-plateau-40

Spec.
Aim
1

1

1

2

3

Table 2.11 - Summary of the source of stray doses for the proton arc therapy treatment plans.
Patient Model

Specific Aim

Source of Neutron Dose
Estimate

Small
Medium
Large

1
1, 2 and 3
1

Fontenot et al. (2008)
Simulations from this work
Fontenot et al. (2008)
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Chapter 3
Results
The results from this work are presented in this chapter. First, the treatment plans and
therapeutic dose determination will be presented (section 3.1). Specifically, details of the
VMAT (section 3.1.1) and proton arc (section 3.1.2) treatment plans are presented, followed by
dose-volume histogram comparisons in section 3.1.3. Next, the results of the stray dose
determination are presented (section 3.2). Finally, section 3.3 presents the predicted ERR values
for VMAT and proton arc therapy, the RRR of the two modalities, the statistical analysis
(section 3.3.1), and the uncertainty analysis (section 3.3.2).
3.1. Therapeutic Dose Distributions
3.1.1. Volumetric Modulated Arc Therapy
The VMAT treatment plans created for specific aim 1 are presented below. Figure 3.1
shows the therapeutic dose using a colorwash scale ranging from 10 Gy (blue) to 80 Gy (red).
The prescribed dose for each patient was 76 Gy (normalized to 78.8 Gy to the mean of the
PTV; section 2.2.1), and the MUs required for the small, medium and large patients‟ treatment
plans were 669, 962, and 920, respectively. For the small patient, the maximum dose was
located in the PTV in the right seminal vesicle and was 107.9%. The maximum dose for the
medium patient was located in the left, inferior, posterior portion of the PTV and was 108.8%.
For the large patient, the maximum dose was located in the PTV in the left seminal vesicle and
was 108.0%. The minimum, mean, and maximum doses to the CTV, PTV, rectum (and
contents), rectal wall, bladder (and contents), and bladder wall for these treatment plans are
presented in Table 3.1, below. In general, the low dose was distributed over a large amount of
healthy tissue, but the high dose was conformed to the PTV. A high dose gradient existed in the
rectum, which was desirable to minimize toxicities and satisfy the DVH constraints (Table 2.2).
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Figure 3.1 - Axial (left) and sagittal (right) CT slices of the small (top), medium (middle), and
large (bottom) patients‟ VMAT treatment plans showing a colorwash of the dose distribution
from 10 Gy to 80 Gy. The CTV is shown in cyan, the PTV in white, the bladder in yellow, and
the rectum in green. The 30 Gy isodose level is represented by cyan.

Table 3.1 - Minimum, mean, and maximum therapeutic doses for the CTV, PTV, rectum and
contents, rectal wall, bladder and contents, and bladder wall for the small, medium, and large
patients for the VMAT treatment plans with nominal margins for specific aim 1.
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The VMAT treatment plans created for specific aim 3 with various size margins around
the CTV are shown below in Figure 3.2. It can be seen that as the margins from the CTV
increase, the high-dose area (red) increases to cover the larger PTV and the medium dose (30
Gy) (cyan) extends further into the rectum. The effect of margin size on dose to the bladder
wall and rectal wall is presented in Table 3.2 and graphed in Figure 3.3 below, where it can be
seen that mean doses to the bladder wall and rectal wall increase as margin size increases.
However, maximum and minimum doses remain relatively constant with increasing
margin size. This is because the bladder wall and rectal wall are already receiving very close to
the maximum dose for the plan. Therefore, as the high dose encroaches further into the organs,
the mean dose increases while the maximum dose remains fairly stable. Similarly, the
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minimum dose to the organs remains relatively constant because it is determined by the dose
far from the target, which is not significantly affected by the size of the high dose region.

Figure 3.2 – Axial images of a sampling of the VMAT treatment plans with varying margin
size around the CTV. Plan indices correspond to those in Table 2.3, where the margins increase
as the plan index increases. The CTV is shown in cyan, the PTV in white, and the rectum in
green. Close-up views of the central region including the CTV, PTV and rectum are inset.
Table 3.2 - Minimum, mean and maximum doses to the bladder wall and rectal wall for VMAT
as a function of margin size around the CTV. Plan indices correspond to Table 2.3, where plan
1 has the smallest expansion and plan 6 has the largest expansion. As expected, mean doses to
both the bladder wall and rectal wall increase as margin size increases.
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Figure 3.3 – Therapeutic mean absorbed dose to the bladder wall and rectal wall as a function
of “else” margin size around the CTV to create the PTV for the VMAT treatment plans for
specific aim 3. Posterior margins are 2 mm less than those graphed, except for 0 mm “else”
expansion, where the posterior margin is also 0 mm. Margin sizes correspond to Table 2.3. The
nominal expansion is 7 mm in the “else” anatomical directions. As expected, mean dose
increases with margin size.
3.1.2 Proton Arc Therapy
The proton arc therapy treatment plans with varying number of treatment beams are
presented below. The mean doses to the bladder (and contents), bladder wall, rectum (and
contents), rectal wall, femoral heads, and normal tissues were plotted vs. the number of
treatment beams. Figure 3.4 demonstrates the weak dependence of mean dose on number of
beams beyond 8 beams. The risk of second cancer of the bladder and rectum was also
calculated for these treatment plans (method described in section 2.4), which also shows a weak
dependence on number of beams (Figure 3.5). Because of the smooth shape of the isodose lines
produced with the 16-field plan (Figure 3.6), we approximated all arc dose distributions using
16 static fields.
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Figure 3.4 – Calculated mean dose (DT) vs. the number of equally spaced and uniformly
weighted treatment beams (n). Little variation is observed beyond 8 beams.

Figure 3.5 – Predicted excess relative risk (ERR) of a second malignant neoplasm in the
bladder and rectum vs. number of equally spaced and uniformly weighted beam angles, n, for
two different risk models. The linear-no-threshold (LNT) model is the least dependent on the
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distribution of dose in a volume, and the linear-exponential-10 (Lexp10) is the most dependent
on the distribution of dose. A weak dependence on the number of beams was observed.

Figure 3.6 - Isodose lines of the 6, 8, 12, and 16-beam treatment plans, showing the 45 Gy
(RBE) (orange), 30 Gy (RBE) (cyan), and 20 Gy (RBE) (yellow) isodose lines, revealing a
significant smoothing with increasing number of beams. 16 beams produced extremely smooth
isodose lines. The CTV is shown in cyan, the PTV in white, and the rectum in green.
The proton arc therapy treatment plans created for specific aim 1 are presented below.
Figure 3.7 shows the therapeutic dose using a colorwash scale ranging from 10 Gy (RBE) to 80
Gy (RBE). For the small patient, the maximum dose was located in the PTV in the seminal
vesicles and was 106.6%. The maximum dose to the medium patient was in the PTV in the
bladder wall and was 105.5%. For the large patient, the maximum dose was within the CTV
and was 105.6%. The minimum, mean, and maximum doses to the CTV, PTV, rectum (and
contents), rectal wall, bladder (and contents), and bladder wall for these treatment plans are
presented in Table 3.3, below. It can be seen that the low dose region encompasses a smaller
overall volume than the VMAT plans (Figure 3.1). On average, proton arc therapy reduced the
volume of normal tissue exposed to doses between 10 and 30 Gy or Gy (RBE) by 73%. The
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high dose region is very conformal, but because proton treatment beams are typically designed
with larger margins, the high dose region is slightly larger in the proton arc therapy plans than
in the VMAT plans. Specifically, the small, medium, and large patients‟ irradiated volumes
(volume receiving at least 76 Gy or Gy (RBE)) were 106, 156 and 159 cm3, respectively, for
proton arc therapy, and 89, 138 and 135 cm3, respectively, for VMAT.

Figure 3.7 - Axial (left) and sagittal (right) CT images of the small (top), medium (middle),
and large (bottom) patients‟ proton arc treatment plans showing a colorwash of the dose
distribution from 10 Gy (RBE) to 80 Gy (RBE). The CTV is shown in cyan, the PTV in white,
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the bladder in yellow, and the rectum in green. The 30 Gy (RBE) isodose level is represented
by cyan.

Table 3.3 - Minimum, mean, and maximum therapeutic doses for the CTV, PTV, rectum and
contents, rectal wall, bladder and contents, and bladder wall for the small, medium, and large
patient for the proton arc therapy treatment plans with uniform beam weighting and nominal
margins for specific aim 1.

The first set of proton arc therapy treatment plans created using non-uniform beam weights
(specific aim 2) is shown below in Figure 3.8 (optimization objectives 1, 2, and 3 from Table
2.5, respectively). The beam angles found through optimization to minimize the combined risk
of second cancer of the bladder and rectum were 90 and 270 degrees, a 2-field lateral-opposed
treatment with equal beam weighting. The beam angles that minimized the risk of second
cancer of the bladder only were posterior oblique beams at 157.5 and 202.5 degrees with equal
weighting. The beam angles that minimized the risk of second cancer of the rectum only were
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anterior oblique beams at 45 and 315 degrees with equal weighting. The minimum, mean, and
maximum doses to the bladder wall and rectal wall from these treatment plans are listed in
Table 3.4.

Figure 3.8 - Proton arc therapy treatment plans with SMN risk-minimized beam weighting for
combined bladder and rectum (A, 90 and 270 degrees with 1:1 weighting), bladder only (B,
157.5 and 202.5 degrees with 1:1 weighting), and rectum only (C, 45 and 315 degrees with 1:1
weighting).
Another goal of specific aim 2 was to determine the optimal beam weighting for a patient
with a prosthetic hip (objective 4 from Table 2.5). The resulting treatment plans are shown in
Figure 3.9 below. The plan labeled “prosthetic hip plan 1” utilized 270 and 292.5 degree beams
with weighting of 1.94:1, respectively. This plan minimized the risk of SMN incidence in the
bladder and rectum, but deposited an unacceptable amount of dose in the healthy femoral head:
15% of the right femoral head received at least 64.8 Gy (RBE). The clinical objective for the
femoral heads is that 15% of the structure should receive no more than 45 Gy (RBE). A second
treatment plan, “prosthetic hip plan 2”, shown on the right in Figure 3.9) utilized 270 and 157.5
degree beams with weighting of 1.94:1, respectively, and met the clinical DVH constraints for
the femoral head, bladder, and rectum. The minimum, mean, and maximum doses to the
bladder wall, rectal wall, and femoral head from these treatment plans are listed in Table 3.4.
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Figure 3.9 - Proton arc therapy treatment plans with SMN risk-minimized beam weighting for
combined bladder and rectum with a prosthetic hip. The figure on the left shows “Prosthetic
Hip Plan 1”, with the angles of 270 and 292.5 degrees and weights of 1.94:1, respectively. The
figure on the right shows “Prosthetic Hip Plan 2”, with angles of 270 and 157.5 degrees and
weights of 1.94:1, respectively. Notice the reduction in high dose to the right femoral head in
prosthetic hip plan 2.
Table 3.4 - Minimum, mean and maximum doses to the bladder wall and rectal wall from
various risk-optimized proton arc therapy treatment plans.

The proton arc therapy treatment plans with varying margins created for specific aim 3
are shown below in Figure 3.10. Similar to the VMAT plans, as the margins from the CTV
increase, the red high-dose region increases to cover the larger PTV and the cyan region of
medium dose (30 Gy (RBE)) extends further into the rectum. The dose to the bladder wall and
rectal wall are presented for each treatment plan in Table 3.5 and graphed in Figure 3.11 below,
where it can be seen that doses to the bladder wall and rectal wall increase as margin size
increases. Similar to the VMAT plans for specific aim 3, the minimum and maximum doses to
the bladder wall and rectal wall are relatively insensitive to margin size (section 3.1.1).
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Figure 3.10 – Axial CT images of a sample of the proton arc treatment plans with varying
margins from the CTV. Plan indices correspond to Tables 2.6 and 2.7, where the margins
increase with plan index. The margins listed on the figure correspond to the margins from the
CTV to create the PTV. Lateral, distal and proximal margins around the CTV can be found in
Tables 2.6 and 2.7. The CTV is shown in cyan, the PTV in white, and the rectum in green. The
colorwash scale is from 10 Gy (RBE) to 80 Gy (RBE). Close-up views of the central region
including the CTV, PTV and rectum are inset.
Table 3.5 - Minimum, mean and maximum doses to the bladder wall and rectal wall for proton
arc therapy as a function of margin size around the CTV. Plan indices correspond to Tables 2.6
and 2.7, where plan 1 has the smallest margin and plan 6 has the largest margin.
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Figure 3.11 – Therapeutic mean dose to the bladder wall and rectal wall as a function of “else”
margin size around the CTV to created the PTV for the proton arc therapy treatment plans for
specific aim 3. Posterior margins are 2 mm less than those graphed, except for the 0 mm “else”
expansion, where the posterior margin is also 0 mm. Plan indices and margin sizes correspond
to Tables 2.6 and 2.7. The nominal expansion is 7 mm “else.” As expected, dose increased with
margin size.
3.1.3. Dose-Volume Histogram Comparisons
Since DVHs are traditionally plotted for the whole organ (including the contents), we
plotted the difference between the traditional whole organ contour and the organ wall contour
in Figures 3.12 and 3.13, below. In general, the organ wall curves are slightly higher, indicating
a larger percentage of the organ receiving a given dose.
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Figure 3.12 - Cumulative dose-volume histogram for the medium patient for VMAT (black;
Gy) and uniformly weighted proton arc therapy (red; Gy (RBE)) nominal treatment plans
created for specific aim 1 showing the difference between therapeutic absorbed dose to the
bladder (and contents) and bladder wall. The bladder wall curves are consistently higher than
the bladder curves.

Figure 3.13 - Cumulative dose-volume histogram for the medium patient for the VMAT
(black; Gy) and uniformly weighted proton arc therapy (red; Gy (RBE)) nominal treatment
plans created for specific aim 1 showing the difference between therapeutic absorbed dose to
63

the rectum (and contents) and rectal wall. In general, the rectal wall curves are higher than the
rectum curves.
Figures 3.14 and 3.15 display the bladder wall and rectal wall DVHs, respectively, for the
VMAT and proton arc therapy treatment plans created for specific aim 1. The results from all
three patients are plotted together. The only obvious dependence on patient size is that the large
patient doses are the highest in all cases. All of the DVH constraints were satisfied for all plans
shown in Figures 3.14 and 3.15 and are quantitatively presented in Table 3.6.

Figure 3.14 - Bladder wall cumulative dose-volume histogram for the small, medium, and
large patients‟ nominal treatment plans for VMAT (black; Gy) and uniformly weighted proton
arc therapy (red; Gy (RBE)) for specific aim 1.
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Figure 3.15 - Rectal wall cumulative dose-volume histogram for the small, medium, and large
patients‟ nominal treatment plans for VMAT (black; Gy) and uniformly weighted proton arc
therapy (red; Gy (RBE)) for specific aim 1.
Table 3.6 - DVH constraints and results for the bladder and rectum for the small, medium, and
large patient treatment plans for specific aim 1 (uniformly weighted proton arc therapy). The
results are shown for the bladder and rectum volumes (including contents) for consistency with
clinically used DVH constraints. All DVH constraints were met.

For specific aim 2, treatment plans were created to investigate the effect of proton beam
weighting on the risk of SMN incidence for proton arc therapy. Figures 3.16 through 3.20
display the DVHs for the bladder wall and rectal wall for the various optimized proton arc
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therapy plans compared to the nominal (uniformly weighted) proton arc therapy plan created
for specific aim 1. Specifically, Figure 3.16 shows the resulting DVH from the risk-optimized
plan where the combined risk of second cancer incidence of the bladder and rectum was
minimized. Then, Figures 3.17 and 3.18 correspond to the treatment plans where the risk of
second cancer of the bladder only and second rectal cancer only, respectively, were minimized.
Finally, the DVHs for the treatment plans for the special case of a patient with a prosthetic hip
are shown in Figures 3.19 (prosthetic hip plan 1) and 3.20 (prosthetic hip plan 2). The DVH for
the right femoral head is also plotted for the prosthetic hip plans, since it is of particular
concern. The quantitative DVH constraints and results for the bladder and rectum are listed in
Table 3.7. All DVH constraints for the bladder and rectum were met, except for the rectal
constraints shown in red for the bladder-only optimized treatment plan.

Figure 3.16 - Cumulative dose-volume histogram for the SMN risk-minimized (bladder and
rectum) beam weighted treatment plan (solid line) for the bladder wall (orange) and rectal wall
(green) for proton arc therapy compared to the nominal equally-weighted treatment plan
(dashed line).
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Figure 3.17 - Cumulative dose-volume histogram for the SMN risk-minimized (bladder only)
beam weighted treatment plan (solid line) for the bladder wall (orange) and rectal wall (green)
for proton arc therapy compared to the nominal equally-weighted treatment plan (dashed line).

Figure 3.18 - Cumulative dose-volume histogram for the SMN risk-minimized (rectum only)
beam weighted treatment plan (solid line) for the bladder wall (orange) and rectal wall (green)
for proton arc therapy compared to the nominal equally-weighted treatment plan (dashed line).
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Figure 3.19 - Cumulative dose-volume histogram for the proton arc therapy prosthetic hip plan
1 (solid line) and the nominal uniformly weighted proton arc therapy plan from specific aim 1
(dashed line). The beam weighting was optimized to minimize the combined risk of second
cancer of the bladder and rectum.

Figure 3.20 - Cumulative dose-volume histogram for the proton arc therapy prosthetic hip plan
2 (solid line) and the nominal uniformly weighted proton arc therapy plan from specific aim 1
(dashed line). The beam weighting was optimized to minimize the combined risk of second
cancer of the bladder and rectum.
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Table 3.7 - DVH constraints and results for the bladder and rectum for the treatment plans
created for specific aim 2 with non-uniform (risk-minimized) beam weighting. The results are
shown for the bladder and rectum volumes (including contents) for consistency with traditional
DVH constraints. All DVH constraints were met, except the rectal constraints shown in red for
the bladder-only optimized plan (50%, 40% and 20% volume constraints).

Figures 3.21 through 3.24 show the cumulative DVHs for the treatment plans created for
specific aim 3 where the margin size around the CTV was varied. The bladder wall and rectal
wall DVHs are shown for the VMAT treatment plans in Figures 3.21 and 3.22, respectively,
and the proton arc therapy treatment plans in Figures 3.23 and 3.24, respectively. It can be seen
that the DVH curve is higher as the treatment margin increases, indicating a larger volume
receiving a given dose. All of the DVH constraints used in the planning process were met for
the VMAT and proton arc therapy plans and are listed in Tables 3.8 and 3.9, respectively.

69

Figure 3.21 - Cumulative dose-volume histogram for the bladder wall for the VMAT treatment
plans for specific aim 3. The margin size around the CTV increased with plan index, revealing
the positive relationship between volume irradiated and margin size.

Figure 3.22 - Cumulative dose-volume histogram for the rectal wall for the VMAT treatment
plans for specific aim 3. The margin around the CTV increased with plan index, revealing the
positive relationship between volume irradiated and margin size.
Table 3.8 - DVH constraints and results for the bladder and rectum for the VMAT treatment
plans with varying margin size. The results are shown for the bladder and rectum volumes
(including contents) for consistency with traditional DVH constraints. All DVH constraints
were met. In general, dose increased with plan index (and margin size).
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Figure 3.23 - Cumulative dose-volume histogram for the bladder wall for the uniformly
weighted proton arc therapy treatment plans for specific aim 3. The margin size around the
CTV increased with plan index, revealing the positive relationship between volume irradiated
and margin size.
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Figure 3.24 - Cumulative dose-volume histogram for the rectal wall for the uniformly weighted
proton arc therapy treatment plans for specific aim 3. The margin around the CTV increased
with plan index, revealing the positive relationship between volume irradiated and margin size.
Table 3.9 - DVH constraints and results for the bladder and rectum for the proton arc therapy
treatment plans with varying margin size. The results are shown for the bladder and rectum
volumes (including contents) for consistency with traditional DVH constraints. All DVH
constraints were met. In general, dose increased with plan index (and margin size) increases.

3.2 Stray Dose Determination
3.2.1 Volumetric Modulated Arc Therapy Stray Dose
The contribution of stray dose (from leakage and scatter photons) for the VMAT
treatment plans was estimated by introducing a correction to out-of-field region (outside the 5%
isodose surface calculated by the TPS) where the TPS underestimates stray radiation (Howell et
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al., 2010a; Howell et al., 2010b). The nominal correction was defined as a 40% increase
applied to the out-of-field dose portion differential DVH for the bladder wall and rectal wall.
The effect of this stray dose estimation is shown in Table 3.10. The largest impact of the 40%
increase on the mean dose was seen in the bladder wall of the medium patient: a difference of
0.43 Gy. Additionally, the lower and upper bounds of the corrected mean dose were found by
increasing the out-of-field dose by 20% and 60%, respectively (Howell et al., 2010a; Howell et
al., 2010b). Then, the percent error in the corrected mean dose was found by dividing the
difference in the upper bound and lower bound mean doses by two, dividing that by the
nominally corrected mean dose, and multiplying by 100. The resulting errors in mean dose
ranged from 0.1% to 1.3%, depending on the patient and the organ (see last row in Table 3.10).
The nominal, corrected differential DVH was used for the risk calculations, described in
section 3.3, and the maximum percent error was used in the uncertainty analysis, described in
section 3.3.2.
Table 3.10 - Effect of the stray dose estimation method on the mean dose of the bladder wall
and rectal wall for each patient. The maximum difference between the nominal corrected value
and the uncorrected value was seen in the bladder wall of the medium patient: a difference of
0.43 Gy. The maximum percent error, 1.3%, was used in the uncertainty analysis described in
sections 2.4.5 and 3.3.2.
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3.2.2 Proton Arc Therapy Stray Dose
The stray dose from proton arc therapy was calculated using Monte Carlo simulations for
the medium patient and estimated from the literature (Fontenot, 2008; Fontenot et al., 2008) for
the small and large patients. The calculated and estimated stray doses are listed below in Table
3.11. The stray rectal dose calculated in this work for the medium patient was slightly higher
than the estimated dose from the work of Fontenot et al., most likely due to the posterior
component of the arc delivery, which was not accounted for in the estimations from the
literature. Another difference in the methodology from the work of Fontenot et al. is that their
values were obtained using 2 cm diameter receptors at the location of the organ in a phantom,
where our work used the mean dose calculated from the organ wall DVH.

Table 3.11 - Stray equivalent doses for the bladder and rectum (and therefore the bladder wall
and rectal wall) for the small, medium and large patients for the whole proton arc therapy
treatment calculated in MCNPX and estimated from Fontenot et al. (2008).
Small Patient
Large Patient
Medium Patient Stray Dose [Sv]
Stray Dose [Sv]
Stray Dose [Sv]
Structure
Our
MCNPX
Estimated from Estimated from
Estimate from
calculations
literature
literature
literature
Bladder
0.82
0.97
0.96
1.06
Rectum
0.61
0.76
1.13
0.88

3.3 Risk Prediction
The predicted risk of SMN incidence following VMAT and proton arc therapy for prostate
cancer at the exposed age of 60 years and the attainted age of 70 years is presented below.
Table 3.12 lists the predicted ERR (sum of bladder and rectum) for the nominal treatment plans
created for specific aim 1 (uniformly weighted for proton arc therapy), and Figure 3.25 shows a
histogram of this data for the medium patient. Additionally, the RRRs (ratios of ERRP

Arc

to

ERRVMAT), are reported in Table 3.13 and plotted in Figure 3.26. For all risk models, the mean
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ERR of all three patients following proton arc therapy was less than that following VMAT,
yielding RRRs of less than one.
Table 3.12 – Predicted excess relative risk of SMN incidence of the bladder and rectum for the
nominal VMAT and proton arc therapy („P Arc‟) treatment plans for prostate cancer for the
linear-no-threshold, linear-exponential, and the linear-plateau risk models for specific aim 1.
The linear-exponential and linear-plateau models had inflection points at 10 Sv and 40 Sv. Risk
was calculated for the small, medium, and large patients, as well as the mean of the three. This
data is shown in histogram form in Figures 3.25 and 3.26.

Figure 3.25 - The predicted excess relative risk of SMN incidence in the bladder and rectum
for the medium patient following VMAT and uniformly weighted proton arc therapy for the
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linear-no-threshold model, linear-exponential model with the inflection point at 10 Sv and 40
Sv, respectively, and the linear-plateau model with the inflection point at 10 Sv and 40 Sv,
respectively.
Table 3.13 – The ratio of excess relative risk (RRR) following uniformly weighted proton arc
therapy relative to the risk following VMAT for specific aim 1. An RRR (ERRP Arc/ERRVMAT)
value less than one indicates a lower risk of SMN incidence following proton arc therapy.

Figure 3.26 – The ratio of excess relative risk of SMN incidence (ERRP Arc/ERRVMAT) following
uniformly weighted proton arc therapy relative to that following VMAT for the small, medium
and large patient for the linear-no-threshold model, linear-exponential model with the inflection
point at 10 Sv and 40 Sv, respectively, and the linear-plateau model with the inflection point at
10 Sv and 40 Sv, respectively.

For specific aim 2, the risk following proton arc therapy with optimized non-uniform beam
weighting was investigated. First, in order for the optimization algorithm to be able to minimize
the risk, the risk contributed by each beam angle (or mirrored pair) had to be determined. Table
3.14 and Figure 3.27 show the ERR calculated with the LNT model at each beam angle (or
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mirrored pair) from therapeutic radiation assuming unit weighting for each. Then, the
appropriate relative beam weighting to minimize the risk of SMN incidence of the bladder and
rectum, bladder only, and rectum only (Table 3.15) was determined. Additionally, optimal
weighting was found to minimize the risk of SMN incidence of the bladder and rectum for the
scenario of a patient with a prosthetic hip (Table 3.16). The results of specific aim 2 are
summarized and compared to specific aim 1 in Figure 3.28, below.
Table 3.14 - The predicted LNT ERR of SMN incidence for the medium patient contributed by
each proton beam or beam pair (therapeutic dose only). These reported risks are for each beam
(or pair) as if it were 100% of the treatment. The beam angles listed are in degrees and refer to
the left (L) and corresponding right (R) mirrored beams, respectively.
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Figure 3.27 - The predicted LNT excess relative risk of SMN incidence for each proton beam
or beam pair (therapeutic dose only). These reported risks are for each beam or beam pair
normalized as if it were 100% of the treatment. It can be seen that there is a minimum in total
risk for the 90 degree and 270 degree beam pair.
Table 3.15 – The non-uniform relative proton beam weights found by the optimization
algorithm and the resulting LNT excess relative risk (ERR) (risk from stray dose included) for
plans optimized to minimize risk of SMN incidence in the bladder and rectum, bladder only,
and rectum only for specific aim 2. The third to last row (Sum: ERRPArc) is the total ERR for the
treatment. The second to last row is the ERR following the same (medium) patient‟s VMAT
treatment plan from specific aim 1 (Table 3.12). The last row (RRR) is the ratio of ERRPArc to
ERRVMAT.
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Table 3.16 - The non-uniform beam weights found by the optimization algorithm and the
resulting LNT risk (ERR) (risk from stray dose included) for the two prosthetic hip plans for
specific aim 2. The third to last row (Sum: ERRPArc) is the total ERR for the treatment. The
second to last row is the ERR following the same (medium) patient‟s VMAT treatment plan
from specific aim 1 (Table 3.12). The last row (RRR) is the ratio of ERRPArc to ERRVMAT.
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Figure 3.28 – The ratio of excess relative risk (RRR) of SMN incidence (ERRP Arc/ERRVMAT)
following proton arc therapy relative to that following VMAT for the medium patient for the
linear-no-threshold model. The RRRs from the proton arc therapy plans with non-uniform beam
weighting optimized for objectives 1, 2, 3 and 4 (Table 2.5) are compared to the RRR from
uniformly weighted proton arc therapy from specific aim 1
Specific aim 3 was designed to investigate the effect of margin size around the CTV to
create the PTV on the predicted risk of SMN incidence following prostate radiotherapies. The
predicted risk of SMN incidence in the bladder and rectum following VMAT and uniformly
weighted proton arc therapy with varying margins for the medium patient is graphed below in
Figures 3.29 through 3.31. First, Figure 3.29 shows the ERR of SMN incidence of the bladder,
rectum, and the combination of the two organs calculated with the LNT model. It can be seen
that the risk of SMN incidence in the bladder is higher than for the rectum and that risk
increases as margin size increases for both. Then, the combined ERR of SMN incidence in the
bladder and rectum for the LNT, linear-exponential, and linear-plateau models for VMAT and
proton arc therapy is plotted in Figure 3.30. As expected, the linear-exponential and linearplateau prediction of ERR is less than for LNT. Finally, the RRR of SMN (ratio of ERRP Arc to
ERRVMAT) is plotted in Figure 3.31. The LNT RRR is highest, around 1 (range: 1.00 – 1.08),
showing little difference between the two modalities and a potential slight advantage for
VMAT. The linear-exponential-10 RRR yielded the lowest RRR, 0.66, showing the largest
advantage for proton arc therapy. As seen before in specific aim 1, all alternative risk models
indicated an advantage for proton arc therapy with RRRs ranging from 0.66 to 0.93. While ERR
generally increases with increasing margin size (within our bounds of 0 mm to 8 mm), a strong
relationship between RRR and margin size was not observed.
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Figure 3.29 – The predicted LNT excess relative risk of SMN incidence of the bladder and
rectum and the combination of the two for the medium patient vs. the “else” margin around the
CTV to create the PTV for VMAT and uniformly weighted proton arc therapy. The nominal
expansion is 7 mm “else.” Posterior margins are 2 mm less than those graphed, except for 0
mm “else” expansion, where the posterior margin is also 0 mm.

Figure 3.30 – The predicted excess relative risk (RRR) of SMN incidence (combined bladder
and rectum) for VMAT and uniformly weighted proton arc therapy for the medium patient for
the linear-no-threshold model, linear-exponential model, and linear-plateau model vs. the “else”
margin around the CTV to create the PTV. The nominal expansion is 7 mm “else.” Posterior
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margins are 2 mm less than those graphed, except for 0 mm “else” expansion, where the
posterior margin is also 0 mm. The linear-exponential and linear-plateau models have inflection
points at 10 Sv and 40 Sv.

Figure 3.31 – The predicted ratio of excess relative risk (RRR) of SMN incidence (combined
bladder and rectum) for the medium patient for the linear-no-threshold model, linearexponential model, and linear-plateau model vs. the “else” margin around the CTV to create the
PTV. The nominal expansion is 7 mm “else.” Posterior margins are 2 mm less than those
graphed, except for 0 mm “else” expansion, where the posterior margin is also 0 mm. The
linear-exponential and linear-plateau models have inflection points at 10 Sv and 40 Sv.
3.3.1 Statistical Analysis
The statistical analysis was performed to test the RRR values from specific aim 1 against
the value of 1 (small sample size, n=3). When the sign test was conducted, the null hypothesis
that P(+) ≥ P(–) (the probability of RRR > 1 being greater than or equal to the probability of
RRR < 1) was rejected for all alternate risk models, but could not be rejected for the LNT
model. Table 3.17 shows the p-values for the sign test for the different risk models, where red
indicates a fail (p > 0.05; could not reject null hypothesis) and green indicates a pass (p < 0.05;
rejected null hypothesis).
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Table 3.17 - The results of the sign test which compared the RRR to 1. Red indicates a fail,
where the null hypothesis that the P(+)≥P(–) cannot be rejected. Green indicates a pass, where
the null hypothesis can be rejected, i.e. the RRR is significantly less than 1.

The t-test yielded similar results: the null hypothesis that the mean RRR ≥ 1 was rejected
for the alternate risk models, but could not be rejected for the LNT model. Table 3.18 shows
the p-values for the t-test for all of the risk models, where red indicates a fail (p > 0.05; could
not reject null hypothesis) and green indicates a pass (p < 0.05; rejected null hypothesis).
Table 3.18 - The results of the t-test which compared the RRR to 1. Red indicates a fail, where
the null hypothesis that the RRR ≥ 1 cannot be rejected. Green indicates a pass, where the null
hypothesis can be rejected, i.e. the RRR is significantly less than 1.

3.3.2 Uncertainty Analysis
The uncertainty was estimated using propagation of the uncertainties of the components of
the risk calculation (equations 2.16a and 2.16b). The uncertainty in the therapeutic absorbed
dose from proton therapy was estimated to be 5% from the work of Giebeler et al. (2009). Two
uncertainties contributed to the total uncertainty in the corrected VMAT dose: the uncertainty
in the TPS VMAT dose (2% (Fontenot, 2008)) and the relative uncertainty in the correction
method for VMAT (1.3% (section 3.2.1)). Therefore, the quadrature sum of 2% and 1.3% was
used for the uncertainty in the corrected VMAT dose,

D1

D1

. The relative uncertainty in the
V
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neutron dose from statistical fluctuations was found with a quadrature sum of the relative
uncertainties of the neutron dose from each beam in the region of the bladder and rectum. The
RRR

RRR

and
wR

RRR

RRR

values were determined with sensitivity analysis, for which the
RM

results are listed in Tables 3.19 and 3.20, respectively. Then, the covariance term was found to
account for the effect of correlations in the data on the uncertainty. In this study, it was a
negative term, which reduced the overall uncertainty. The absolute value of the covariance term
was found to be 3.5% using equation 2.17 and the last term in equation 2.16. The final
uncertainty in the mean RRR was asymmetric and calculated to be +1.2% and -22.7%. All
uncertainty values are listed in Table 3.20 below.
Table 3.19 – The mean LNT ERRs for uniformly weighted proton arc therapy and respective
RRRs. As a sensitivity test, the mean radiation weighting factor for neutrons was varied by
factors ranging from 0.5 to 5. The denominator for the mean RRR calculation (last row) is the
LNT ERR for VMAT for each patient (Table 3.12).

Table 3.20 – Assumed and calculated relative uncertainties for the error propagation and the
resulting total uncertainty (equations 2.16a and b). The total uncertainties (positive and
negative) are also reported in absolute terms of RRR (in parentheses). One σ corresponds to the
68% confidence interval.
Term
Description
Value [%]
Uncertainty in therapeutic
D1
absorbed dose from proton
5.0
arc therapy
D1 P
(TPS)
Uncertainty in dose from
D1
VMAT (corrected TPS: see
2.4
D1 V
section 3.2.1)
Statistical uncertainty in
D2
stray absorbed dose from
< 1.0
proton arc therapy
D2 P
(Monte Carlo)
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RRR

RRR

wR

RRR

RRR
2

RM

ERRV ERRP

ERR V ERR P
RRR

RRR
RRR

RRR

Uncertainty contributed from
wR

4.7

Uncertainty contributed from
the risk model

26.2

Covariance term for VMAT
and Proton Arc Therapy

-3.5

Total positive uncertainty in
mean RRR

1.2 (0.01)

Total negative uncertainty in
mean RRR

22.7 (0.22)

In addition, the uncertainty was propagated for each patient individually, which can be seen
as the error bars in Figure 3.32.

Figure 3.32 – The predicted LNT RRRs for the small, medium and large patients (treatment
plans from specific aim 1). The error bars correspond to the uncertainty propagated according
to equations 2.18a and 2.18b.
Finally, uncertainty was also propagated for the mean RRR without the term that accounts
for uncertainty in wR . Then, the mean RRR was plotted vs. wR with error bars that correspond
to the uncertainty in all factors except wR (Figure 3.33).
85

Figure 3.33 – Mean RRRs (Table 3.19; treatment plans from specific aim 1) vs. varying wR
with error bars that include all uncertainties considered, except those in wR .

Chapter 4
Discussion and Conclusion
This chapter begins with a summary of the outcome of the specific aims (section 4.1) and a
comparison with existing literature (section 4.2). Then, the implications and significance
(section 4.3), strengths (section 4.4), and limitations (section 4.5) of this work are discussed.
Finally, possible future work is mentioned (section 4.6) and the conclusions are stated (section
4.7).
4.1 Outcome of the Specific Aims
4.1.1 Outcome of Specific Aim 1
The goal of specific aim 1 was to predict the RRR of SMN incidence of the bladder and
rectum following uniformly weighted proton arc therapy relative to that following VMAT
using calculated dose distributions and risk models. Specifically, the LNT risk model was used
to predict a baseline RRR, and the linear-exponential and the linear-plateau risk modes were
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applied to estimate the impact on RRR from non-linearities in the risk model at high doses. The
mean RRR for the LNT risk model was 0.99 (+ 0.01 or - 0.22; Table 3.20), which was shown to
be not statistically different from 1. The reason for this similarity in LNT risk was that the
mean doses to the bladder wall and rectal wall were comparable for both modalities. However,
the distribution of the dose was more concentrated for proton arc therapy, which resulted in
predicted RRRs that were statistically less than 1 for the other risk models. The mean RRRs
were 0.74, 0.86, 0.84, and 0.91 for the linear-exponential-10 and -40, and linear-plateau-10 and
-40 models, respectively. These results are 8% to 25% lower than the RRR obtained with the
LNT model.
4.1.2 Outcome of Specific Aim 2
The goal of specific aim 2 was to investigate the effect on RRR of optimized proton beam
weighting. Various host and treatment factors were considered, such as type of second cancer
and avoidance of a hip prosthesis on the predicted risk following proton arc therapy. When the
sum of LNT risk of SMN incidence in the bladder and rectum was minimized for proton arc
therapy, the optimization yielded two lateral arc beams, resulting in an RRR of 0.87, compared
to the RRR of 1.06 for uniformly weighted proton arc therapy. When the LNT risk of SMN
incidence in the bladder or rectum alone was minimized, the predicted RRRs were 1.02 and
1.07, respectively. Then, the constraint to avoid beams that passed through a prosthetic hip was
applied while the risk of SMN incidence in the bladder and rectum combined was minimized,
resulting in an RRR of 0.93.
The results of this specific aim show that optimized (non-uniform) beam weighting for
proton arc therapy can significantly lower the predicted RRR of SMN incidence. As expected,
the lowest RRR was achieved when the combined risk of SMN incidence in the bladder and
rectum was minimized for the proton arc therapy plan. Another interesting result from this
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specific aim is the optimal beam orientation to minimize risk of SMN incidence for a patient
with a contralateral prosthetic hip while sparing the healthy femoral head.
4.1.3 Outcome of Specific Aim 3
The goal of specific aim 3 was to examine the sensitivity of the predicted risk of SMN
incidence on the size of the expansion margin around the CTV following both proton arc
therapy and VMAT. Using the LNT model, the ERR was found to vary between 6.83 and 10.07
for proton arc therapy and 6.55 and 9.52 for VMAT, where risk increased with increasing
margin size. The lowest ERR of SMN incidence was for the linear-exponential-10 model,
which was found to vary between 0.88 and 0.90 for proton arc therapy and 1.28 and 1.32 for
VMAT. In general, the ERR values calculated with the linear-exponential and linear-plateau
risk models were less sensitive to margin size. Moreover, the RRR of SMN incidence was
virtually independent of margin size for all risk models, with an average of 1.04, 0.69, 0.88,
0.81 and 0.90 for the LNT, linear-exponential-10 and -40, and linear-plateau-10 and -40
models, respectively.
4.2 Comparison with Existing Literature
The study most similar to this work is by Fontenot et al. (2009). In their study, the ERRs of
SMN incidence in the bladder, rectum, and various out-of-field organs were calculated for the
same three patients following parallel-opposed beam proton therapy and compared with
corresponding ERRs following 6 MV IMRT. Additionally, they calculated the RRR for the
medium patient with the same alternate risk models used in this work. They found the average
RRR for all three patients to be 0.68 for the LNT model, and the RRR for the medium patient to
be 0.66, 0.69, 0.69, 0.60, and 0.62 for the LNT, linear-exponential-10 and -40, and linearplateau-10 and -40 models, respectively. When only the colon and bladder are included in their
calculation, the RRR for the medium patient becomes 0.65, 0.62, 0.64, 0.57, and 0.59 for the
LNT, linear-exponential-10 and -40, and linear-plateau-10 and -40 models, respectively.
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The largest numerical difference between RRR predictions from the work of Fontenot et al.
and this work was for the case of the LNT model: 0.66 vs. 1.06, respectively. An obvious
source of this difference is that Fontenot et al. studied static-beam therapies, where we
considered arc therapies. In our study, we found the ERR for equally-weighted 360 degree
proton arc therapy to be considerably higher than for parallel-opposed beam proton therapy:
11.51 vs. 7.97. This lower value for parallel-opposed beams compares fairly well to the ERR
reported by Fontenot et al. for the bladder and colon of 6.24; however, there are other subtleties
that account for the remaining discrepancy. First, Fontenot et al. used the whole organ volume
(including contents), while we used the organ wall (excluding contents). We showed that this
can have a significant impact on the mean organ dose, and therefore the LNT ERR. For
example, in our study, the mean doses (therapeutic radiation only) to the bladder (and contents)
and bladder wall from a parallel-opposed beam treatment were 9.34 Gy (RBE) and 13.40 Gy
(RBE), respectively. Second, the mean dose to the target was slightly lower in the study by
Fontenot et al. When their treatment plan was normalized to the same mean target dose as
prescribed in our study, their mean doses to the bladder and bladder wall were 9.19 Gy (RBE)
and 13.16 Gy (RBE), respectively, which agree very well with those from our study (listed
above). To illustrate how this affects the risk, a table of the LNT ERR of SMN incidence in the
bladder (and contents), bladder wall, rectum (and contents), and rectal wall from therapeutic
dose is shown below (Table 4.1) for the two studies (normalized to the same target dose).
Table 4.1 - The therapeutic dose component of ERR for the treatment plans in this study (LR)
and the study by Fontenot et al. (2009) (JF) calculated with the LNT model for the bladder (and
contents), bladder wall, rectum (and contents), and rectal wall. Note the increase in risk when
the organ walls were used instead of the whole organ. For the proton plans (last three columns)
„2 beam‟ refers to a parallel-opposed proton beam treatment for prostate (accomplished with
weighting for the proton arc plan), where „Uniform‟ refers to the 360 degree, uniformly
weighted proton arc treatment plan. While the „2 beam‟ proton plans have comparable risk, the
„Uniform‟ proton arc treatment plan has higher risk.
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Therefore, when differences in planning technique (arc plans vs. static beam plans, prescription
dose) and volume contouring (wall volumes vs. whole organ volumes including contents) are
considered, our results agree well with those from Fontenot et al.
Schneider et al. (2007) also published a study that is relevant to this work. In their study,
the whole-body secondary cancer risk of spot-scanned proton radiotherapy relative to 6 MV
IMRT was found to be 0.49, 0.50, and 0.51 for the LNT, linear-exponential, and linear-plateau
models, respectively. Because of the spot-scanning delivery, dose from external neutrons was
minor, in contrast to our work, where it comprises approximately one third of the neutron dose.
However, the contribution of external neutron dose to the total risk was minimal:
approximately 2%. Another difference in their study is that they did not do tissue-specific risk
calculations; they estimated risk to a “whole-body” contour. Despite the differences in the
methods, our results are remarkably consistent with the results from Schneider et al.
This study is not consistent with the work of Dasu et al. (2011). They predicted the risk of
second cancers in the bladder and rectum following 3DCRT of the prostate for “narrow”
margins (4 mm in the posterior direction, 6 mm in other directions) and “wide” margins (10
mm in the posterior direction, 15 mm in other directions) around the CTV. They predicted risk
using a model based on the single-dose competition model proposed by UNSCEAR (1993),
which is similar to the linear-exponential model in our work. They found that the risk decreased
with larger margins, whereas we found that risk either remained approximately constant

90

(linear-exponential-10) or increased slightly (linear-exponential-40) with margin size (Figure
3.30). However, there are a few major differences in our studies. First, the risk model used by
Dasu et al. peaks at about 4 Gy, where ours peaked at either 10 or 40 Gy (Gy is equivalent to
Sv for photons). Second, the distribution of dose for 3DCRT treatment plans could be
significantly different from the distribution of dose for our VMAT and proton arc therapy
treatment plans. Finally, the “wide” margins used in their work were considerably larger than
the largest margins investigated in our work (10 mm vs. 6 mm in the posterior direction, and 15
mm vs. 8 mm in other directions, respectively). It is possible that these differences account for
the discrepancy in the results between the two studies.
4.3 Implications and Significance of this Study
Due to the large population of patients who receive prostate radiotherapy, even a small
increase or decrease in risk of cancer due to radiation exposure could have a significant impact
on public health. Therefore, risk of SMN incidence following treatment should be considered,
along with many factors, in the clinical and policy decision making. The significance of this
work is that it characterizes the risk of SMN incidence following two types of radiotherapy for
prostate cancer: VMAT and proton arc therapy.
Previous to this work, the risks of SMNs following radiation arc therapies using VMAT and
proton arc therapy were unknown. In this work, the ERR and RRR for the two modalities were
characterized for the two modalities for a variety of host and treatment factors: patient size,
proton arc therapy beam weighting, mean neutron radiation weighting factor, risk model, and
margin size.
Another finding of this work was the ideal proton beam arrangement to minimize the risk of
SMN in the bladder and rectum for a patient with a prosthetic hip. It is possible that this finding
could be one factor in the choice of beam angles for such patients.
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In addition, this study found that two lateral-opposed proton beams is the ideal arrangement
to minimize the risk of second cancers of the bladder and rectum following prostate
radiotherapy. This result is encouraging in regard to statically delivered proton therapy, because
it strengthens the rationale for the beam arrangement in the current standard-of-care used for
treating for prostate cancer. However, it is something that should be taken into consideration in
the development of proton arc therapy. Therefore, an implication of this finding is that it would
be advantageous for a proton arc therapy machine, which has been proposed but not yet built,
to have the capability to deliver this type of lateral-opposed treatment, e.g. static or near-static
beam delivery capacity.
4.4 Strengths of this Study
This study has several noteworthy strengths. First, to our knowledge, this was the first study
to explicitly and algorithmically minimize the risk of second cancer by varying proton beam
weights. Others have investigated minimizing risk through choice of treatment modality
(Miralbell et al., 2002; Mu et al., 2005; Schneider et al., 2006; Fontenot et al., 2009;
Newhauser et al., 2009a; Bednarz et al., 2010) or optimizing treatment plans for uncertainties
(Pflugfelder et al., 2008; Unkelbach et al., 2009) or RBE (Wilkens and Oelfke, 2005), but this
was the first study to specifically optimize treatment plans to minimize the risk of second
cancers. This method could be expanded upon and applied to other treatment sites. In the
future, minimizing a patient‟s risk for developing a second cancer could be one of the many
factors in personalized cancer radiotherapy.
Additionally, our study was the first to estimate the risk of SMN incidence following
VMAT for prostate cancer. Surprisingly, we found the risk of SMN in the bladder and rectum
following VMAT to be lower than following IMRT. This result is of particular interest due to
the recent expansion of VMAT and because of the ubiquity of photon-based external beam
radiotherapy for prostate cancer.
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Another strength of this study was the level of detail of the dose determination and risk
estimation. Differential DVHs were exported from the TPS for the bladder and rectum,
excluding the contents, and stray dose was estimated or calculated where possible. Then, age-,
sex-, and organ-specific parameters were obtained from BEIR VII, used to estimate the LNT
risk, and modulated to model cell sterilization with the linear-exponential and linear-plateau
risk models.
Finally, the uncertainty analysis was a strength of this work. Other similar works mention
the uncertainties associated with risk predictions (Kry et al., 2005a; Schneider et al., 2007;
Bednarz et al., 2010) but did not report a full uncertainty propagation. In this work, we
extended and adapted the uncertainty analysis of Fontenot et al. (2008; 2010) and included
uncertainties in the dose (both therapeutic and stray), the neutron radiation weighting factor,
and the risk model.
4.5 Limitations of this Study
There are several limitations of this study. First, only the risk of SMNs of the bladder and
rectum were considered. This is not a serious limitation, however, because doses to the bladder
and rectum account for the vast majority of the risk (Fontenot et al., 2009); the risks of SMN
incidence in the bone marrow, skin, and out-of-field organs, which were not included in this
study, are of lesser importance.
Moreover, the metric used in this work to express risk of SMN, ERR, has limitations of its
own. ERR is an instantaneous quantity, describing the excess relative risk at a given point in
time. In this work, the ERR at 10 years post-treatment was chosen as a meaningful surrogate for
the lifetime ERR for the purposes of estimating RRR, giving the typical age of prostate cancer
patients. Therefore, this is not a major limitation of this work.
Additionally, only three patients were studied in this work. While a strong dependence on
patient-specific differences (patient size, internal anatomy) was not observed in this work, the
93

sample size was small. Studying a larger patient population would elucidate the dosimetric
impact of inter-patient anatomical differences, and might make it possible to see a larger,
statistically significant difference in the predicted mean RRR value.
Another limitation of this study was that risk-optimized treatment planning was not
explicitly available for VMAT. However, the inverse planning method used for all of the
VMAT treatment plans was conceptually and functionally similar to the risk-optimized
planning method utilized for the proton arc therapy treatment plans for specific aim 2. Both
optimization methods minimized the dose to organs of interest: e.g. the bladder and/or rectum.
The VMAT inverse planning system accomplished this with a cost function that was based on
DVH objectives and constraints for the organs of interest. The risk-minimized proton arc
therapy treatment planning method also minimized dose to the bladder and rectum with a cost
function, which was based on mean organ dose. Because of these similarities, we believe that
the comparison between the modalities was reasonable. For future work, it would be interesting
to investigate risk-optimized planning for VMAT.
Furthermore, range compensators were used to create distal conformity for the proton arc
treatment plans in this study. If this technique was implemented using passive scattering,
different range compensators could not be used for each beam. Either one generic range
compensator could be used, or none at all. However, the goal of this study was to investigate
the risk of SMN incidence following proton arc therapy in general, not to address all of the
design challenges of implementing proton arc therapy on a passively scattered system.
Additionally, if scanned beam delivery was used for proton arc therapy, which has its own
engineering challenges, range compensators would not be necessary for distal conformity.
The final noteworthy limitation is that variations in the dose distribution (beyond those
observed in our sample) were not considered in the uncertainty analysis of RRR. The dose
distribution for both modalities could be affected by uncertainty in the beam calibration, setup
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errors, varying field size, and differences in anatomy. In particular, the dose distribution for
proton arc therapy could also be affected by the beam range, SOBP width, and the air gap.
4.6 Future Work
Treatment-specific measurements to validate the stray dose that was estimated and
simulated for this work would lend additional confidence to their accuracy. Due to the
difficulty of detecting high-energy neutrons, the stray dose from proton arc therapy would have
to be measured with a special detector like an extended Bonner Sphere system (Howell, 2009)
or a WENDI-II (Olsher and McLean, 2008). Additionally, stray dose from VMAT has not been
explicitly characterized. Even though extensive stray dose measurements have been made for
IMRT (Kry et al., 2005b; Howell et al., 2006), verifying that the stray doses between the two
modalities are equivalent would be valuable.
This work focused on SMNs of the bladder and rectum. For a more complete representation
of the risk of SMN incidence following radiotherapy, the risk calculations could be expanded to
include bone marrow, skin, and other out-of-field organs. However, the BEIR VII report does
not include specific risk prediction information for skin, and excludes non-melanoma skin
cancers. Therefore, another reference would be required for the inclusion of skin, for example,
Publication 60 of the ICRP (1991). Also, our patient CT datasets did not span the entire body,
so additional whole-body phantoms would be necessary for the Monte Carlo simulations.
Finally, this work could be expanded to other treatment sites and patient populations. A
different treatment location yields different doses to organs, thus producing a different risk
profile. A different patient population would have a different risk of second cancer based on
age at exposure and life expectancy. For example, children treated with radiation have an
increased risk of cancer due to increased radiosensitivity (ICRP, 1991) and the potential for a
longer life expectancy post treatment. Because of these factors, it would be particularly
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meaningful to study and minimize the predicted risk of second cancers following radiotherapy
for pediatric patients.
4.7 Conclusions
Proton arc therapy significantly reduces the predicted risk of incidence of radiogenic second
malignant neoplasms (SMNs) in the bladder and rectum following prostate radiotherapy
compared to VMAT when predicted with the linear-exponential and linear-plateau risk models.
On the other hand, no significant difference was seen between the modalities when the risk was
predicted with the linear-no-threshold (LNT) model. When the beam weighting for proton arc
therapy was optimized to minimize the LNT risk of SMN incidence, a reduction of risk was
observed compared to VMAT: RRR was reduced from 1.06 to 0.87. Additionally, it was found
that while excess relative risk (ERR) of SMN incidence increased with PTV margin size for
both modalities, the ratio of excess relative risk (RRR) between the two modalities was virtually
independent of margin size.
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